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Preface
This year, the EMCDDA marks 25 years of reporting on the European drug situation. We are 
proud of the contribution the agency has made during this period to foster the European 
dialogue on drugs. Our approach has been to provide stakeholders with a neutral and balanced 
assessment of not only the problems Europe faces, but also what constitutes effective 
solutions. The agency’s work is now recognised as one of the foundations for drug policy 
discussions. In a field in which many hold strong personal views and consensus is not always 
easy to reach, we believe the impartiality and objectivity of our work is a core strength of the 
EMCDDA. The European drug problem has changed substantially over the last 25 years, but 
our primary objective of providing reliable evidence remains as important today as it was when 
the agency was founded. We are pleased, therefore, to present here the European Drug Report 
(EDR) 2020, which comes along with a concise multilingual summary (the EDR Key Issues).
This year is different, however. Our annual reporting exercise is intended to provide 
a synthesis of the most recent data available; in this case describing the European drug 
situation up to the end of 2019. From early 2020 the global COVID-19 pandemic has 
dramatically altered all aspects of modern life and this includes drug use, the drug market and 
the ability of European countries to provide help and support to those with drug problems. 
Our immediate response to the pandemic was to help our stakeholders through the sharing 
of information on how services could both protect their staff and continue to deliver essential 
care and support to those in need. 
We have also launched a series of ongoing rapid assessments to understand the impact of 
the pandemic on drug use, associated problems and the market. This information is available 
on our dedicated webpages for COVID-19. As the situation is highly dynamic, assessments 
can quickly become obsolete. The online resources therefore provide the most up-to-date 
analysis of the current situation.
As we move forward, we must also recognise that the events of 2020 are likely to have a long-
term impact on the future challenges arising in the drugs area. As the ‘new normal’ begins 
to take shape, we will need to monitor if and how quickly the situation returns to how it was 
before COVID-19. This year’s EDR will function as a baseline for this further analysis. Many 
of the developments we note here will remain serious challenges in the coming years. At the 
same time, the economic impact of the pandemic and the legacy effects on behaviours and 
services are likely to have lasting repercussions that will feed into the challenges awaiting us 
in the future. We believe that the European Drug Report of 2020 provides a sound evidence 
base for preparing for the post-pandemic period. The problems we face may differ but 
the EMCDDA remains committed to providing in the coming years the same high-quality, 
impartial and evidence-based assessments as we have in the past.
Finally, at this time of significant upheaval, we wish to extend a special thanks to our partners 
in the Reitox network of national focal points, our other national and international partners 
and the Scientific Committee of the EMCDDA, whose support has been essential for this 
report. We also gratefully acknowledge the contribution of the many European research 
groups who have helped enrich the analysis presented here and the input we have received 
from our European partners: the European Commission, Europol, the European Medicines 
Agency and the European Centre for Disease Prevention and Control. 
Laura d’Arrigo  
Chair, EMCDDA Management Board 
Alexis Goosdeel  
Director, EMCDDA
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5Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the 
candidate country Turkey, and Norway, in an annual reporting process. 
The purpose of the current report is to provide an overview and summary of the European 
drug situation up to the end of 2019. All grouping, aggregates and labels therefore reflect the 
situation based on the available data in 2019 in respect to the composition of the European 
Union and the countries participating in EMCDDA reporting exercises. However, not all data 
will cover the full period. Due to the time needed to compile and submit data, many of the 
annual national data sets included here are from the reference year January to December 
2018. Analysis of trends is based only on those countries providing sufficient data to 
describe changes over the period specified. The reader should also be aware that monitoring 
patterns and trends in a hidden and stigmatised behaviour like drug use is both practically 
and methodologically challenging. For this reason, multiple sources of data are used for the 
purposes of analysis in this report. Although considerable improvements can be noted, both 
nationally and in respect to what is possible to achieve in a European level analysis, the 
methodological difficulties in this area must be acknowledged. Caution is therefore required 
in interpretation, in particular when countries are compared on any single measure. Caveats 
relating to the data are to be found in the online Statistical Bulletin, which contains detailed 
information on methodology, qualifications on analysis and comments on the limitations in 
the information set available. Information is also available there on the methods and data 
used for European level estimates, where interpolation may be used. 
The EMCDDA would like to thank the following for their help in producing this report:
I  the heads of the Reitox national focal points and their staff; 
I  the services and experts within each Member State that collected the raw data for  
this report;
I  the members of the Management Board and the Scientific Committee of the EMCDDA;
I  the European Parliament, the Council of the European Union — in particular its Horizontal 
Working Party on Drugs — and the European Commission;
I  the European Centre for Disease Prevention and Control (ECDC), the European Medicines 
Agency (EMA) and Europol;
I  the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and 
Crime, the WHO Regional Office for Europe, Interpol, the World Customs Organisation, the 
European School Survey Project on Alcohol and Other Drugs (ESPAD), the Sewage Analysis 
Core Group Europe (SCORE), the European Drug Emergencies Network (Euro-DEN Plus), 
the European Syringe Collection and Analysis Project Enterprise (ESCAPE) network and the 
Trans-European Drug Information network (TEDI).
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network 
is comprised of national focal points in the EU Member States, the candidate country 
Turkey, Norway and at the European Commission. Under the responsibility of their 
governments, the focal points are the national authorities providing drug information 
to the EMCDDA. The contact details of the national focal points may be found on the 
EMCDDA website.
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The analysis presented in this report is based on the most 
recent data available from routine monitoring and describes 
the drug situation in Europe at the end of 2019. Since 
then, European countries have been greatly affected by the 
outbreak and rapid spread of the coronavirus disease 2019 
(COVID-19) pandemic. The enforcement of restrictive public 
health measures necessary to curb transmission of the 
virus have impacted all areas of life including drug use, drug 
markets and the implementation of law enforcement and 
health and social responses to the drug phenomenon. Across 
Europe, 2020 has seen, to varying degrees, the introduction 
of restrictive measures unprecedented in peacetime, 
including closure of non-essential services, border closures, 
and limitations on the right to assembly and freedom of 
movement. This situation has had an immediate impact on 
many behaviours linked to drug use and drug supply, as well 
as disrupting health provision and some law enforcement 
activities. Subsequently, the relaxing or lifting of some of 
the public health measures has created the conditions for 
a rebound towards the pre-COVID-19 situation. However, 
at the time of writing, the situation remains volatile and the 
pandemic continues to have an impact across many key 
policy areas, including drugs. Importantly, COVID-19 still 
poses a major threat to global health and security and is likely 
to do so for some time. The pandemic is also likely to have, in 
the medium to long term, an economic and social impact that 
will have wide-ranging implications, including some for the 
future problems we are likely to face in the drugs area.
From the start of the pandemic, the EMCDDA has been 
committed to supporting its stakeholders in responding to 
the immediate challenges in this area. The EMCDDA has 
been closely following the development of the situation and 
responses to it, acting as a conduit for information-sharing. 
In a series of rapid studies, we have also reported on the 
impact of COVID-19 on drug use and associated problems, 
help-seeking, service provision and the operation of the drug 
market. The situation requires regular review and our ongoing 
work on it can be accessed from our COVID-19 web area.
This includes an analysis of the special needs and risks 
for people who use drugs, in order to prevent coronavirus 
infections among this group. While people who use drugs 
run the same risk of coronavirus infection as the general 
population, they also face additional risks and vulnerabilities 
that need both consideration and mitigation. A rapid 
trendspotter assessment conducted by the EMCDDA found 
that some behaviours associated with drug taking prior to 
the COVID-19 pandemic may now be considered ‘high-risk’ 
in terms of infection. For example, sharing cannabis joints or 
cocaine straws, sharing preparation equipment among high-
risk drug users (e.g. crack pipes, spoons, filters), and splitting 
and handing over MDMA tablets may all pose potentially 
new and little-explored risks of coronavirus transmission at 
the moment of drug taking. Moreover, some conditions linked 
to drug use may make individuals more likely to experience 
adverse outcomes if they do become infected. For example, 
people with chronic opioid and stimulant use problems 
are more likely to have compromised immune systems, 
chronic respiratory disease — for example linked to smoking 
tobacco and other drugs — and cardiovascular disease. 
Chronic health problems combined with the poor living 
conditions often associated with high-risk drug use may 
make people both more susceptible to coronavirus infection 
and in danger of more severe consequences if infected. 
Drug problems are also commonly found in marginalised 
groups like the homeless and in criminal justice settings, 
where COVID-19 prevention measures can be particularly 
challenging. There is also a concern that any disruptions 
to the drug market may result in dependent drug users 
COVID-19 PANDEMIC 
AND THE DRUG 
SITUATION
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turning to different substances or engaging in more risky 
behaviours. It also appears that in some countries, possibly 
as a result of disruptions to local drug markets, COVID-19 
has resulted in greater help-seeking among people who use 
drugs. This added to the operational pressures on services 
that were introducing measures to mitigate the impact of the 
pandemic on their clients and staff.
During the initial lockdown period, harm reduction and drug 
treatment services, like all healthcare providers, were faced 
with the difficulties of providing continuity of care while 
reducing face-to-face contact and respecting travel bans 
and other social distancing measures. While services have 
experienced disruptions, innovative approaches to providing 
care have helped to counteract this. These innovations 
include introducing more flexibility in substitution treatment 
prescribing and the provision of harm reduction material, 
greater use of e-and m-health options and a more proactive 
approach to outreach with clients who faced mobility 
restrictions. It will be interesting to see if these changes alter 
service provision in the long term. A less positive observation 
is that as some services for people who use drugs are 
often delivered by voluntary or civil society groups, they 
may not always be well integrated into healthcare systems. 
During the initial stages of the pandemic, this resulted in 
concerns that these kinds of services were not included in 
COVID-19 prevention measures being applied to other areas 
of healthcare, such as ensuring the availability of personal 
protective equipment. A valuable lesson for the future is the 
need to ensure the inclusion of community-based services in 
crisis response and contingency planning. 
The EMCDDA, in collaboration with Europol, has released 
an initial analysis of the of impact of COVID-19 on drug 
markets in the European Union. At first, local drug markets 
appeared to be affected by social distancing measures 
as people who use drugs reported that supplies of some 
drugs were disrupted, resulting in higher prices. However, 
these changes appeared short-lived, with subsequent 
reports indicating that retail markets are reappearing as 
social distancing measures are relaxed. Other changes 
in the drugs market were observed, including a possible 
increased interest in online sales via darknet markets, 
with drug distributors adapting their methods to fit the 
COVID-19 situation. Generally, since the emergence of the 
pandemic, surface web and darknet markets, social media 
and secure encrypted communication applications now 
appear to be playing a more prominent role in the sourcing 
of drugs at the user level. Less face-to-face dealing and 
less reliance on cash as a form of payment seem to be 
increasing for individual transactions, and it is possible that 
behavioural changes, once established, will persist. There 
were also some signs of declining interest in substances 
like MDMA and cocaine that are commonly used in social 
settings, which were not operational during lockdowns. 
There were, however, also reports of a greater interest in or 
use of some more novel substances. An example was the 
appearance of benzodiazepines on the new psychoactive 
substances market, possibly driven in part by shortages 
of more established drugs. From the information currently 
available, the overall impact on patterns of drug taking 
appears somewhat mixed, with differences observed 
between countries. It will remain to be seen whether any 
trends triggered or accelerated by the pandemic take 
root and become part of future consumption patterns; for 
example, in more interest in online drug sales or increased 
popularity of some previous novel substances.
Regarding international drug trafficking and the operation 
of organised crime groups, an initial observation was that, 
unsurprisingly, trafficking using couriers on commercial 
airlines or other forms of public transportation was 
disrupted. However, seizures and intelligence data did not 
suggest any immediate major disruption to major drug 
trafficking activities using other methods, particularly those 
exploiting the movement of commercial goods, in particular 
concealing drugs in shipping containers. Concerns have 
also been raised that organised crime groups may be 
attempting to exploit the current situation, where law 
enforcement officers have been assigned to COVID-19 
prevention activities. There does not appear to have 
been a significant impact on drug production within the 
European Union. Synthetic drug production, for example, 
continues in the main European producing zone in the 
Netherlands and Belgium, as evidenced by the number 
of illicit laboratories dismantled and dumpsites reported. 
The domestic production of herbal cannabis also appears 
not to have been significantly disrupted. Additionally, the 
movement of bulk quantities of drugs between EU Member 
States has continued, despite the introduction of border 
controls, due to the continued commercial transportation 
of goods throughout the European Union. Nonetheless, 
the current instability has led to an increasingly volatile 
environment for criminal businesses along the supply chain 
in Europe and appears to have resulted in increased levels 
of violence among mid-level suppliers and distributors. 
Looking to the future, three important questions remain 
to be answered. Will we see a full return to the situation at 
the end of 2019 and, if so, how quickly will this happen? 
In addition, will there be important medium and long-term 
implications for drug use and the future drug problems we 
face, or for how services respond to problems in this area? 
And finally, what lessons can be learnt from the pandemic 
in order to increase the resilience of our policy responses in 
this area if faced by future crises? The data reported here 
provide a valuable baseline for these considerations, and the 
EMCDDA is committed to following these issues closely. 
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EUROPE’S DRUG  
SITUATION UP TO 2020: 
CURRENT AND 
EMERGING THREATS
Large drug shipments are increasingly intercepted 
Many indicators for the most commonly used substances 
suggest drug availability remains high. Alongside 
developments in production, an increase in the interception 
of large quantities of cocaine, cannabis resin and 
increasingly heroin transported by sea often in intermodal 
containers raises concerns around the infiltration by 
organised crime groups of logistical supply chains, shipping 
routes and large ports. 
Cocaine’s role in Europe’s drug problem is increasing 
The number and quantity of cocaine seizures are now the 
highest ever reported, with over 181 tonnes of the drug 
seized in 2018. Belgium, Spain and the Netherlands are key 
countries for the interception of large quantities. Indicators 
point to high availability of cocaine on the European market 
and signs of growth in countries where it was previously 
uncommon. Crack cocaine use, while still uncommon, is now 
reported by more countries. The purity of cocaine at retail level 
has increased almost every year since 2009, and in 2018 
it reached the highest level in the last decade. Collectively, 
the high purity of the drug, along with data from treatment 
services, emergency presentations and drug-induced deaths, 
suggest that cocaine is now playing a more important role in 
the European drug problem. The cocaine market also appears 
an important driver for drug-related violence. 
The potential for increased heroin use and existing 
harms raise concerns 
Indicators of heroin use continue to suggest an ageing 
cohort of users with low rates of initiation. In addition, new 
drug treatment entries associated with heroin have fallen 
in many countries. However, a doubling of the volumes of 
heroin seized within the European Union and increasing 
volumes seized in Turkey are worrying, as are reports of 
heroin manufacturing taking place within the European 
Union. This suggests more vigilance is necessary to 
detect any signs of increased consumer interest in a drug 
associated with serious health and social problems. 
Understanding the public health impact of high-
potency cannabis and new products 
Cannabis now plays a major role in drug treatment 
admissions, but the relationship between cannabis 
problems and developments in the drug market remains 
poorly understood. This is at a time when the cannabis 
market is changing, with the presence of high-THC 
(tetrahydrocannabinol) content products, and new forms 
of cannabis and commercial products based on extracts 
from the cannabis plant becoming increasingly available. 
Moreover, cannabis resin and herb now contain on average 
about twice as much THC as they did just a decade ago. 
Taken together this suggests that there is a pressing need 
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for greater surveillance in this area. These issues and 
others like the availability of low-THC products marketed 
for their high CBD (cannabidiol) content are examined in 
a forthcoming edition of EMCDDA’s Cannabis: controversies 
and challenges series of briefings.
Increased and diverse drug production within Europe 
Established and new drugs continue to be produced in 
Europe, for local and global markets, with more laboratories 
and production sites detected by law enforcement. Changes 
in the production tactics of organised crime groups are part 
of the reason behind this trend, but also access to cheaper 
and novel precursor chemicals and processing equipment. 
The production of illicit drugs is now based on a more diverse 
set of chemicals, which are both difficult to respond to under 
European and international laws and challenging to monitor. 
Continuing availability of high-strength MDMA 
products highlights need for greater user awareness 
Innovation and scaling-up of synthetic drug production in 
Europe is evident in the continued availability of high-content 
MDMA tablets and high-purity powders. Alongside increases 
in both the average MDMA content in tablets and the purity 
of powders in 2018, data show that products containing 
extremely high levels of MDMA are also being detected. 
These products pose considerable health risks for people 
using them and raise an important issue for prevention and 
harm reduction messaging and interventions.
Growing complexity in the drug market poses 
regulatory challenges and health risks 
A better understanding of the availability of both 
uncontrolled and less common substances, and their impact 
on public health, is clearly needed. These substances are 
often poorly monitored, but there is evidence to suggest 
they may constitute a growing problem, as indicated for 
example by the increased quantities seized of ketamine, 
GHB (gamma-hydroxybutyrate) and LSD (lysergic acid 
diethylamide). In addition, concerns have been raised by 
some countries about the use of substances like nitrous 
oxide (N2O, laughing gas). Non-controlled and new 
benzodiazepines, obtained online or through the more 
conventional illicit drug market, are also a growing concern. 
Etizolam, for example, which is not an authorised medicine 
in most countries, appears to be commonly available on drug 
markets in some countries and has been linked to increases 
in drug-induced deaths among people who use opioids.
Drug overdose is increasingly associated with an 
ageing population 
Between 2012 and 2018 the number of drug overdose 
deaths among the 50-plus age group increased by 75 %, 
indicating that this problem is increasingly associated with 
older long-term users. This underlines the need to recognise 
the increasing vulnerability of an ageing cohort of life-long 
drug users and make this group an important target for 
treatment, social reintegration and harm reduction measures. 
New tools and innovative strategies are needed to 
support the scaling-up of hepatitis C treatment 
Drug injection remains a major route for hepatitis C 
virus (HCV) infections in Europe, and access of people 
who inject drugs to prevention, testing and treatment 
for hepatitis C is therefore a critical requirement for the 
elimination of this disease. While effective oral direct-acting 
antiviral medications are now more available, scaling up 
the provision of these medicines remains a challenge for 
many countries. The introduction of improved diagnostic 
and surveillance techniques to identify those chronically 
infected with this disease is important for the targeting of 
treatment to those most in need. 
New psychoactive substances have become a more 
persistent problem 
The pace at which new psychoactive substances are being 
introduced onto the market has stabilised in recent years. 
Nonetheless, more than 50 new psychoactive substances 
continue to be detected for the first time annually by the 
EU Early Warning System (EWS). Alongside this, each year 
about 400 previously reported new psychoactive substances 
are detected on the European market. 
Appearance of new synthetic opioids is a worrying 
example of continuing market adaptability 
Growing awareness about the individual and public health 
risks associated with fentanyl derivatives has resulted in 
actions that include increased restrictions in producer 
countries. One sign of the market adapting may be that of 
the eight new synthetic opioids detected for the first time in 
2019 by the EWS, six were not fentanyl derivatives, though 
potentially presenting a similar threat to public health.
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For the complete set of data and information on the methodology, see the accompanying online Statistical Bulletin.
Cannabis Cocaine
Heroin and other opioids
3.5 % 0.2 %
21.8 % 5.3 %
AT A GLANCE — ESTIMATES OF DRUG USE IN EUROPE 
Last year use Last year use
Last year use
Principal drug in 
about 34 % of all 
drug treatment 
requests in the 
European Unionopioid users received substitution 
treatment in 2018
Opioids are 
found in 
82 % of fatal 
overdoses
Last year useNational estimates 
of use in last year
National estimates 
of use in last year
Lifetime use Lifetime use
Adults (15-64)
Drug treatment requestsHigh-risk opioid users Fatal overdoses
Adults (15-64)
Young adults (15-34) Young adults (15-34)
25.2 m
7.6 %
34 %
1.3 million
660 000
4.3 m
1.3 %
18.0 m
15.0 %
2.9 m
2.4 %
90.2 m
27.2 %
82 %
17.9 m
5.4 %
Lowest Lowest
Highest Highest
7.6+92.4+x 1.3+98.7+x
2.4+97.6+x
5.4+94.6+x27.2+72.8+x
15+85+x
Amphetamines
0.0 %
3.0 %
Last year use
Last year use National estimates 
of use in last year
Lifetime use
Adults (15-64)
Young adults (15-34)
2.0 m
0.6 %
1.4 m
1.2 %
12.3 m
3.7 %
Lowest
Highest
1.3+98.7+x 3.7+96.3+x
1.3+98.7+x
MDMA
0.2 %
6.9 %
Last year use
Last year use National estimates 
of use in last year
Lifetime use
Adults (15-64)
Young adults (15-34)
2.7 m
0.8 %
2.3 m
1.9 %
13.6 m
4.1 %
Lowest
Highest
1.3+98.7+x 3.7+96.3+x
2.4+97.6+x
34+66+x 82+18+x
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Drug use encompasses a set of complex 
and often hidden behaviours that are 
challenging to monitor. Data sources 
are often partial or incomplete, they 
may not always be directly comparable, 
and they may suffer from time delays in 
reporting. Practical and methodological 
issues therefore exist that impact on 
the collection, reporting and analysis of 
information in this area. The EMCDDA 
approach is to consider multiple 
indicators and review the data regularly 
over time to help detect important 
underlying trends.
EUROPE’S  
DRUG SITUATION 
UP TO 2020
Drug supply and the market
Sizeable markets for cannabis, heroin and amphetamines 
have existed in many European countries since the 1970s 
and 1980s. Over time, other substances also became 
established — including MDMA and cocaine in the 1990s. 
The European drug market continues to evolve, with a wide 
range of new psychoactive substances emerging over 
the last decade. Recent changes in the illicit drug market, 
largely linked to globalisation and new technology, include 
innovation in drug production and trafficking methods, the 
establishment of new trafficking routes and the growth of 
online markets.
In the global context, Europe is an important market 
for drugs, supplied from both domestic production and 
trafficking from other world regions. South America, West 
Asia and North Africa are important source areas for 
illicit drugs entering Europe, while China is an important 
source country for new psychoactive substances, drug 
precursors and related chemicals. In addition, some drugs 
transit Europe en route to other continents. Europe is also 
a  producing region for cannabis and synthetic drugs; 
cannabis production is mostly for European consumption, 
while synthetic drugs are manufactured for the European 
market and exported to other parts of the world.
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The recent (2019) joint EMCDDA-Europol analysis of 
developments in the drug market also provides context for 
the update on trends presented here. That report noted 
that the drug supply chain was more globally connected 
and increasingly digitally enabled, resulting in drug markets 
that are quick to innovate and to exploit new opportunities. 
This presents increasing challenges for current regulatory 
models and law enforcement strategies and accounts for the 
increasing diversity in drug availability and use described in 
this report. The increasing importance of the drug market as 
a driver of crime, particularly corruption and violence within 
EU countries, as well as in other source and transit regions, 
was also noted. This underlines the need to recognise both 
the direct and indirect negative impact of drugs on the 
health and security of European citizens.
More than a million seizures of 
illicit drugs: cannabis dominates 
Seizures of illicit drugs by law enforcement agencies are an 
important market indicator, with around 1.3 million seizures 
reported in 2018 in Europe, with cannabis products most 
often seized (Figure 1). The majority of reported seizures 
involve small quantities of drugs confiscated from users. 
However, a small number of multi-kilogram consignments 
Number of reported drug seizures, breakdown by drug, 2018
FIGURE 1
account for most of the total quantity of drugs seized. This 
underlines the importance of big seizures in interpreting 
data in this area: the detection or non-detection of small 
numbers of shipments can have a significant impact on 
overall totals. The three countries that report the highest 
numbers of seizures, together accounting for over half of 
all drug seizures reported in the European Union, are Spain, 
the United Kingdom and France. However, data on the 
number of seizures are not available for the Netherlands, 
an important country for synthetic drug production, while 
2015 data are the most recent available for Germany, adding 
a considerable degree of uncertainty to the analysis of total 
European seizures.
Drug use prevalence and trends
Drug use in Europe encompasses a wide range of substances. 
Among people who use drugs, polydrug consumption is 
common but challenging to measure, and individual patterns 
of use range from experimental to habitual and dependent 
consumption. Cannabis is the most commonly used drug 
— the prevalence of use is about five times that of other 
substances. While the use of heroin and other opioids remains 
relatively rare, these continue to be the drugs most commonly 
associated with the more harmful forms of use, including 
injecting. The extent of stimulant use and the types that are 
most common vary across countries, and evidence is growing 
of a potential increase in stimulant injecting. Use of all drugs 
is generally higher among males, and this difference is often 
accentuated for more intensive or regular patterns of use.
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Europe’s drug situation up to 2020
Around 96 million adults have 
used illicit drugs
Around 96 million or 29 % of adults (aged 15-64) in the 
European Union are estimated to have used illicit drugs at least 
once in their lifetime. This should be regarded as a minimum 
estimate due to reporting biases. Experience of drug use is 
more frequently reported by males (57.8 million) than females 
(38.4 million). The most commonly tried drug is cannabis 
(54.6 million males and 35.7 million females), with much lower 
estimates reported for the lifetime use of cocaine (12.1 million 
males and 5.8 million females), MDMA (9.1 million males and 
4.6 million females) and amphetamines (8.1 million males and 
4.1 million females). Levels of lifetime use of cannabis differ 
considerably between countries, ranging from around 4 % of 
adults in Malta to 45 % in France.
Last year drug use provides a measure of recent drug use and 
is largely concentrated among young adults. An estimated 
20.0 million young adults (aged 15-34) used drugs in the 
last year (16.6 %), with about twice as many males (21 %) as 
females (12 %) reporting doing so.
Data sources: monitoring drug 
supply, use and harms
The analysis presented here draws on data from both 
demand side and supply side indicators. As noted above 
all indicators are imperfect in some respects and therefore 
analysis needs to take into consideration different data sets, 
and conclusions can only be drawn with caution. 
Supply side sources considered here include data on drug 
seizures, drug precursor seizures and stopped shipments, 
dismantled drug production facilities, retail drug prices, 
purity and potency. In some cases, the absence of seizure 
data from key countries makes the analysis of trends 
difficult. A range of factors can influence trends, including 
user preferences, changes in production and trafficking, law 
enforcement priorities, activity levels and effectiveness. 
Also presented here are data on notifications and seizures 
of new psychoactive substances reported to the EU Early 
Warning System (see the EMCDDA website for more 
information). As this information is drawn from case reports 
rather than routine monitoring systems, seizure estimates 
represent a minimum. 
A wide range of demand-side data sources are also 
included in this analysis. The EMCDDA collects and 
maintains datasets that cover drug use and patterns of 
use in Europe. Surveys undertaken among school students 
and the general population provide an overview of the 
self-reported prevalence of drug use. These survey results 
are complemented by community-level analyses of drug 
residues in municipal wastewater, carried out in cities 
across Europe. 
Studies reporting estimates of high-risk drug use are used 
to identify the extent of the more entrenched drug use 
problems, while data on those entering specialised drug 
treatment systems increase our understanding of the nature 
and trends in high-risk drug use. 
Other, more targeted data sources are also used here. 
Data collections from the analysis of wastewater, 
syringe residues, drug content and drug-related hospital 
emergencies provide insights into changing drug-use 
patterns and types of drug used. While not representative 
of the general population, these sources provide timely 
supplementary data. All data sources on drug use have 
strengths and weaknesses, and both the availability and the 
quality of data can vary by country.
Drug-related infectious diseases and mortality associated 
with drug use are the principal health harms monitored 
systematically by the EMCDDA. These are complemented 
by more limited data on acute drug-related hospital 
emergency presentations and data from the EU Early 
Warning System, which monitors harms associated with 
new psychoactive substances.
Full data sets and methodological notes can be found in the 
online Statistical Bulletin.
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CANNABIS risks
prevention seizures
treatment
trends
use
Cannabis is the illicit drug most widely available in Europe, where 
it is both produced domestically and imported. It is also the most 
commonly used illicit drug. This section analyses the latest data from law 
enforcement, general population surveys and specialised drug treatment 
centres in order to draw a picture of cannabis in Europe, encompassing 
the market, use and related problems.
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CANNABIS
Cannabis seizures: quantity of 
resin increases, herb fluctuates
In 2018 EU Member States reported 760 000 seizures of 
cannabis products, including 412 000 seizures of herbal 
cannabis, 318 000 of cannabis resin and 21 000 of cannabis 
plants. However, the quantity of cannabis resin seized was 
more than three times that of herbal cannabis (668 versus 
194 tonnes). In part, this is a consequence of cannabis 
resin being trafficked in larger volumes across international 
borders, making it more likely to be seized. Because of its 
proximity to Morocco, Spain is particularly important when it 
comes to cannabis resin seizures, accounting for more than 
two thirds (65 %) of the total quantity seized in the European 
Union in 2018 (Figure 2).  
The numbers of cannabis seizures reported in the European 
Union, both for resin and herbal products, have been 
relatively stable since 2012 (Figure 3). In recent years, the 
trend in the volume of seizures has been upwards. Following 
a decline in 2015 the quantity of herbal cannabis seized 
has been fluctuating in many countries. The overall increase 
between 2016 and 2017, mainly due to increases reported 
in Greece, Spain and in particular Italy, was not sustained in 
2018. However, a number of countries that generally seize 
small quantities of herbal cannabis showed considerable 
increases in 2018. One example is Belgium, where the 
17.3 tonnes seized was 18 times the amount seized in the 
previous year. In each year since 2009 Turkey has seized 
more herbal cannabis than any EU country.
Seizures of cannabis plants may be regarded as an indicator 
of the production of the drug within a country. However, 
differences between countries, both in law enforcement 
priorities and reporting practices, mean the data must be 
interpreted with caution. The number of plants seized in 
Europe peaked at 7 million in 2012, before dropping to 
2.5 million plants in 2015, and increasing to 3.3 million 
plants in 2018. European countries reported 350 seizures of 
cannabis oil in 2018, with Belgium (178 litres in 53  seizures) 
and Italy (143 litres and 8 kilograms in 33 seizures) 
accounting for the largest quantities. 
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FIGURE 2
SEIZURES OF CANNABIS RESIN AND HERBAL CANNABIS, 2018 OR MOST RECENT YEAR
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FIGURE 3
TRENDS IN THE NUMBER OF CANNABIS SEIZURES AND QUANTITY OF CANNABIS SEIZED: RESIN AND HERB
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Analysis of indexed trends among those countries 
consistently reporting price and potency data shows an 
overall increase in the potency of both herbal cannabis and 
cannabis resin since 2008. The latest data suggest that 
the THC content of resin sold in Europe is now on average 
almost twice that of herbal cannabis, with half the countries 
reporting a mean potency of 9-12 % for herbal cannabis, 
compared with 13-24 % for resin. Drivers of this increasing 
average potency in resin may include the introduction 
of high-potency cannabis plants and new production 
techniques in Morocco and, to a lesser extent, the greater 
use within Europe of extraction techniques that produce 
higher-potency products. Data suggest that the retail price 
per gram is similar for resin and herbal cannabis and that the 
prices have remained relatively stable since about 2009.
Drug law offences:  
cannabis predominates
The implementation of laws is monitored through data on 
reported drug law offences. The numbers reflect differences 
in national legislation and priorities and also the different 
ways in which the laws are applied and enforced. 
In 2018 an estimated 1.5 million drug law offences were 
reported in the European Union, an increase of about a fifth 
(22 %) since 2008. Most of these offences (75 %) related 
to use or possession, totalling around 1.2 million offences. 
Drug use or possession offences involving cannabis 
continued to increase. Three quarters (75 %) of use or 
possession offences involved cannabis. The upward trend 
in offences for MDMA use or possession continued in 2018, 
although they still only accounted for 2 % of use-related 
offences (Figure 4).
Overall, the number of drug supply offences in the European 
Union has increased by 7 % since 2008, with an estimate 
of more than 230 000 cases in 2018. Again, cannabis 
dominates, accounting for 57 % of supply offences. Reports 
of supply offences for MDMA have been rising since 2011 
(Figure 4), whereas offences related to the supply of cocaine 
have increased mainly in the last two years. The situation for 
heroin was relatively stable over the same period.
Data are for offences for which the drug has been reported.
FIGURE 4
DRUG LAW OFFENCES IN THE EUROPEAN UNION RELATED TO DRUG USE OR POSSESSION FOR USE OR DRUG SUPPLY: 
INDEXED TRENDS AND REPORTED OFFENCES IN 2018
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FIGURE 5
LAST YEAR PREVALENCE OF CANNABIS USE AMONG YOUNG ADULTS (15-34): SELECTED TRENDS AND MOST RECENT DATA
Age ranges other than 15-34 are reported by Denmark, Estonia, Sweden, United Kingdom and Norway (16-34), Germany, France, Greece, Hungary  
and Malta (18-34).
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Cannabis use among young people
It is estimated that 90.2 million adults in the European Union 
(aged 15-64), or 27.2 % of this age group, have used cannabis 
at least once in their lifetime. Around 15 % (18.0 million) of 
young adults (aged 15-34) report using cannabis in the last 
year, with males being typically twice as likely to report use 
than females. Among the 27 countries that undertook surveys 
between 2014 and 2018, considerable variation exists, with 
last year use rates among young adults ranging from 3.5 % in 
Hungary to 21.8 % in France. When only 15- to 24-year-olds 
are considered, the prevalence of cannabis use is higher, with 
19 % (10.4 million) having used the drug in the last year and 
10 % in the last month (5.5 million).
In most countries, recent survey results show either stable 
or increasing last year cannabis use among young adults. 
Of the countries that have produced surveys since 2017 
and reported confidence intervals, eight reported higher 
estimates, three were stable and one reported a decrease 
compared with the previous comparable survey. In eight of 
these countries, an increase in use among 15- to 24-year-
olds has been reported in the most recent survey.
Few countries have sufficient survey data to permit 
statistical analysis of long-term trends in last year use 
among young adults (15-34). Where these exist, the results 
vary, although among some of the higher-prevalence 
countries there are increases between the most recent 
surveys. France shows a weak upward movement since 
2005, with similar values for 2014 and 2017 of 22.1 % 
and 21.8 % respectively (Figure 5). Prevalence is stable in 
Spain at a relatively high rate but with an increase between 
2015 and 2017 from 17.1 % to 18.3 %, while Germany has 
a weak upward movement since 2012, with an increase 
between 2015 and 2018 from 13.3 % to 16.9 %. Finland has 
an upward trend since 2000 and the United Kingdom since 
2012, both with increases in 2018, reaching 15.5 % and 
13.4 % respectively. Belgium reported new survey results for 
2018, with a prevalence of 13.6 %, up from 10.1 % in 2013. 
In contrast, the three surveys in Sweden since 2015 have 
reported a stable prevalence, with 7.9 % in 2018.
Percent
 >15.0
 10.1-15.0
 5.1-10.0
 <5.1
 No data
Under embargo until 22 September 2020 at 10.00 Lisbon/11.00 CET
CANNABIS USERS IN TREATMENT
19
Cannabis
Apart from trends, data are for all treatment entrants with cannabis as primary drug. Trends in first-time entrants are based on 24 countries. Only countries  
with data for at least 11 of the 13 years are included in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data 
at national level, data since 2014 for Italy are not comparable with earlier years. United Kingdom data for 2018 do not include Northern Ireland. 
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High-risk cannabis use:  
a stable picture 
From surveys of the general population, it is estimated that 
around 1 % of adults in the European Union are daily or almost 
daily cannabis users — that is, they have used the drug on 
20 days or more in the last month. The majority of these 
(60 %) are under 35 and around three quarters are male. 
When considered alongside other indicators, data on those 
entering treatment for cannabis problems can provide 
information on the nature and scale of high-risk cannabis 
use in Europe. In 2018 around 135 000 people entered 
specialised drug treatment in Europe for problems related 
to cannabis use (32 % of all treatment demands); of those, 
about 80 000 were entering treatment for the first time. In 
the 24 countries with available data, the overall number 
of first-time entrants for cannabis problems increased by 
64 % between 2006 and 2018. Fifteen countries reported 
an increase between 2006 and 2018 and 14 reported an 
increase in the last year (2017-2018). 
Overall, 50 % of primary cannabis users entering treatment 
for the first time in 2018 reported daily use of the drug in the 
last month, with figures ranging from 10 % or less in Latvia, 
Hungary and Romania to 68 % or more in Spain, France, 
Lithuania and Turkey. Those entering treatment for problems 
related to cannabis are predominantly male, with a ratio of 
just under five males to each female.
Health and social response options for cannabis problems
  Prevention programmes, such as multicomponent school interventions that develop social competences and refusal 
skills, healthy decision-making and coping, and correct normative misperceptions about drug use; family interventions; 
and structured computer-based interventions.
  Brief interventions, for example, motivational interviewing delivered in emergency departments or primary care settings.
  Treatment: research suggests that cognitive behavioural therapy, motivational interviewing and contingency 
management can reduce cannabis use and harm in the short term; multidimensional family therapy can help reduce 
use in high-severity young patients; and some web- and computer-based interventions can reduce cannabis use in the 
short term.
  Harm reduction interventions, for example, addressing the harms associated with smoking cannabis, especially when 
used together with tobacco.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
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COCAINE risks
prevention seizures
treatment
trends
use
Cocaine is the second most commonly used illicit drug in Europe overall, 
although prevalence levels and trends differ considerably between 
countries. The drug is produced from the leaves of the coca plant, grown 
in South America, from where it is trafficked into Europe. Data presented 
in this chapter from law enforcement sources, population surveys and 
specialised drug treatment centres are complemented by findings from 
wastewater analyses and drug checking services. 
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Cocaine seizures reach  
record levels
In 2018 the number of cocaine seizures and the quantity 
seized in the European Union reached the highest levels 
ever recorded, with more than 110 000 seizures of cocaine 
reported, amounting to 181 tonnes. The quantity of cocaine 
seized surpassed the previous record, from 2017, by more 
than 42 tonnes (see Figure 6). Belgium (53 tonnes), Spain 
(48 tonnes) and the Netherlands (40 tonnes) together 
accounted for 78 % of the estimated EU total in 2018, but 
large quantities were also reported by France (16.3 tonnes), 
Portugal (5.5 tonnes) and Italy (3.6 tonnes). 
Small but increasing seizures of coca leaves have also 
been observed (243 kilograms in 2018), as have small 
seizures of coca paste (184 kilograms). This may indicate 
a diversification in production tactics by some criminal 
organisations. Cocaine laboratories found in Europe in the 
past have mainly been ‘secondary extraction facilities’, where 
cocaine is recovered from materials in which it has been 
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EU + 2 refers to EU Member States, Turkey and Norway. Price and purity 
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incorporated (such as wines, clothes and plastics), rather 
than laboratories manufacturing cocaine from coca leaves 
or paste. Seizures of certain chemicals in Spain and the 
Netherlands also support this finding.
The average purity of cocaine at retail level varied from 
23 % to 87 % across Europe in 2018, with half the countries 
reporting an average purity between 53 % and 69 %. Among 
those countries consistently providing data on purity and 
price, the purity of cocaine has been on an upward trend 
over the past decade and in 2018 reached a level 44 % 
higher than the index year of 2008. Over the same period, 
the retail price of cocaine has remained stable. Considered 
along with the seizure data, these indicators suggest that 
cocaine availability in Europe is at an unprecedented level. 
Limited data on drug purity are also available from 
European drug checking services, which test samples 
submitted by individuals. While these services only 
exist in some countries and the data they provide are 
not representative of the market as a whole, the picture 
emerging lends support to recent reports on the increased 
availability and use of high-purity cocaine. 
In the period January-June 2019 cocaine was the 
substance most frequently submitted to European drug 
checking services for testing. In total, 1011 samples 
presented as cocaine were analysed and reported by 
11 services operating in eight EU Member States. More 
than half (57 %) of all samples presented as cocaine 
contained only cocaine and inactive compounds (e.g. milk 
powder). In 4 % of the samples, cocaine was not detected. 
The remaining 40 % of samples contained a combination 
of cocaine and one or more pharmacologically active 
adulterants, with levamisole the most common, found in 
184 samples, followed by caffeine (146 samples). Data 
on cocaine purity were available for 852 cocaine samples 
from seven drug checking services operating in six EU 
Member States. The average purity of cocaine samples 
was 69 % (73 % during the same period in 2018), with one 
in every two samples containing more than 75 % cocaine 
(Figure 7). According to information provided by the 
clients, about two thirds (65 %) of the samples presented 
as cocaine were obtained through direct contact with 
a known supplier. 
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FIGURE 6
NUMBER OF POWDER COCAINE SEIZURES AND QUANTITY 
SEIZED: TRENDS AND 2018 OR MOST RECENT YEAR
COCAINE SAMPLES TESTED BY DRUG CHECKING SERVICES 
BETWEEN JANUARY AND JUNE 2019
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Indications of increased  
cocaine use 
Surveys suggest that around 18 million adults aged 15-64 in 
the European Union (5.4 %) have used cocaine at least once 
in their lifetime. Of those aged 15-34, nearly 3 million (2.4 % 
of this age group) are estimated to have used the drug in the 
last year. 
Among the 27 countries that undertook a survey 
between 2014 and 2018, prevalence of last year cocaine 
use among young adults ranged from 0.2 % to 5.3 %, 
with eight countries reporting rates of more than 2.5 % 
(Figure 8). Of the 12 countries that have conducted 
surveys since 2017 and reported confidence intervals,  
five reported higher estimates than their previous survey 
and seven had stable estimates. 
A statistical analysis of long-term trends in last year use 
of cocaine among young adults (15-34) is only possible 
for a small number of countries, among which there is 
some evidence of increased use. The United Kingdom has 
observed an upward trend since 2015, reaching 5.3 % in 
2018. Upward trends have also been reported by France 
(2000 to 2017), reaching 3.2 %, and by Finland (2010 to 
2018), reaching 1.5 %. Not all trends are upward. Spain has 
reported a decline in use since 2008, though prevalence 
in the last two years has been stable, and prevalence in 
Norway has remained largely stable since 2013. Without 
notable trends, increases in prevalence between the last 
two surveys were reported for 2018 by Germany (2.4 % as 
opposed to 1.2 % in 2015) and Estonia (2.8 % as opposed 
to 1.3 % in 2008). Similarly, increases were reported for 
2017 by Denmark (3.9 % as opposed to 2.4 % in 2013) 
and Sweden (2.5 % as opposed to 1.2 % in 2013). 
Analysis of municipal wastewater for cocaine residues 
carried out in a multi-city study complements, but is 
not directly comparable to, the results from population 
surveys. A 2019 analysis found the highest mass loads 
of benzoylecgonine — the main metabolite of cocaine 
— in cities in Belgium, Spain, the Netherlands and the 
United Kingdom.
The most recent data indicate that cocaine is becoming 
more common in eastern European cities, although 
detection levels remain low (see Figure 9). Of the 45 cities 
that have data for 2018 and 2019, 27 reported an increase, 
10 a stable situation and 8 a decrease. Increasing longer-
term trends are observable for most of the 14 cities with 
data covering the 2011 to 2019 period. 
FIGURE 8
LAST YEAR PREVALENCE OF COCAINE USE AMONG YOUNG ADULTS (15-34): SELECTED TRENDS AND MOST RECENT DATA
Age ranges other than 15-34 are reported by Denmark, Estonia, United Kingdom and Norway (16-34), Sweden (17-34), Germany, France,  
Greece and Hungary (18-34).
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FIGURE 9
Increase in people seeking 
treatment related to cocaine use 
The prevalence of high-risk cocaine use among adults in 
Europe is difficult to gauge as only four countries have 
recent estimates. In addition, these estimates are not 
directly comparable, as they have been generated using 
different definitions and methodologies. In Spain, a general 
population survey used high frequency of use to estimate 
high-risk cocaine use at 0.3 % among people aged 15-64 
in 2017/18. In 2018, based on a national survey, Germany 
estimated that 0.1 % of the adult population showed 
indications of cocaine dependence; Italy, using treatment 
and criminal justice data, estimated that 0.7 % of the adult 
population could be classified as high-risk cocaine users. 
In France, a 2017 capture-recapture study estimated the 
prevalence of high-risk crack cocaine use at 0.07 %. In 
the United Kingdom, a study covering the 2016-17 period 
estimated the prevalence of crack use among the population 
aged 15-64 years in England to be 0.5 %.
Spain, Italy and the United Kingdom account for almost three 
quarters (72 %) of all reported specialised treatment entries 
related to cocaine in Europe. Overall, cocaine was cited as 
the primary drug by 75 000 clients entering specialised 
drug treatment in 2018 of which 34 000 were first-time 
(new) clients. 
After a period of decline, the overall number of cocaine first-
time treatment entrants has been on an upward trend, with 
22 countries reporting increases between 2014 and 2018.
The latest European data reveal a time lag of 11 years 
between first cocaine use, on average at the age of 23, and 
first treatment for cocaine-related problems, on average at 
the age of 34. 
The majority of those who enter specialised treatment citing 
cocaine as their main problem drug are powder cocaine 
users (57 000 or 13 % of all drug clients in 2018). Around 
half of Europe’s 15 000 crack-related treatment demands 
are reported by the United Kingdom, where it is also the 
substance most often reported as a secondary drug by all 
drug clients. The remaining crack users are reported mainly 
by Belgium, Spain and France. A caveat here is that the term 
‘crack’ may not be used consistently by all countries. 
COCAINE RESIDUES IN WASTEWATER IN SELECTED EUROPEAN CITIES: TRENDS AND MOST RECENT DATA
Mean daily amounts of benzoylecgonine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year from 
2011 to 2019. Source: Sewage Analysis Core Group Europe (SCORE).
mg/1 000 population/day
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COCAINE USERS ENTERING TREATMENT
Apart from trends, data are for all treatment entrants with cocaine as primary drug. Trends in first-time entrants are based on 24 countries. Only countries with data 
for at least 11 of the 13 years are included in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data at national 
level, data since 2014 for Italy are not comparable with earlier years. United Kingdom data for 2018 do not include Northern Ireland. 
 Germany  Other countries  Italy 
 United Kingdom  Spain
 Injecting, 2 %
 Smoking/inhaling, 27 %
 Eating/drinking, 2 %
 Sniffing, 68 %
 Other, 1 %
Trends in first-time entrantsCharacteristics Frequency of use 
in the last month
Route of administration
16 % 84 %
23Mean age at first use Mean use 4.1 days per week
Daily
2 to 6 days 
per week
Once a week 
or less
Not used in the 
last 30 days
34Mean age at treatment entry
Previously 
treated entrants 
52 %
First-time 
entrants 48%
36 900
34 200
27 %
37 %
17 %
20 %
52+48+x 2.4+27+2+68+1+x
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Health and social response options for cocaine problems
  Brief interventions, referral to treatment programmes or harm reduction services can be offered when users seek help 
at emergency departments for problems related to intoxication or high-dose use.
  Stimulant injectors need regular access to needle and syringe programmes because they may inject more often than 
opioid users during the course of a binge.
  Outreach programmes may be necessary to deliver harm reduction interventions to stimulant users who would not 
otherwise access services.
  Treatment using psychosocial interventions, and especially contingency management, can be effective for problematic 
cocaine use. 
  Pharmacological treatments may help reduce cocaine use in people with concurrent opioid use problems.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
The use of cocaine in combination with heroin or other 
opioids was reported by 59 500 clients entering specialised 
drug treatment in Europe in 2018. This number represents 
15 % of all treatment entrants for whom both primary and 
secondary drug information is available.
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AMPHETAMINES
risks
prevention seizures
treatment
trends
use
The synthetic drugs amphetamine and methamphetamine are central 
nervous system stimulants, which in many data sets are grouped together 
as amphetamines. Of the two drugs, amphetamine is more commonly 
available in Europe, whereas significant methamphetamine use has 
historically been restricted to the Czechia and, more recently, Slovakia. 
Data presented in this chapter from law enforcement sources, population 
surveys and specialised drug treatment centres are complemented by 
findings from wastewater analyses and drug checking services. 
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AMPHETAMINES
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EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of amphetamines: national mean values — minimum, 
maximum and interquartile range. Countries covered vary by indicator. Indexed trends are not available for methamphetamine.
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Amphetamine and 
methamphetamine seizures: 
domestic production
Both methamphetamine and amphetamine are produced 
in Europe. Amphetamine is more widely available, but 
seizure data suggest that methamphetamine availability has 
increased, with the drug being detected in more countries. 
Data indicate that amphetamine production takes place 
mainly in the Netherlands, Belgium and Poland, and to a 
lesser extent in the Baltic States and Germany. Seizures of 
concentrated amphetamine oil, which is converted through 
crystallisation into the salt form, represent a new challenge 
for law enforcement within the European Union, as this 
suggests that the final stage of production is now sometimes 
occurring at or near its intended destination point. 
Some amphetamine is also manufactured in the European 
Union for export, principally to the Middle East. Large 
seizures of amphetamine tablets with a ‘Captagon’ logo have 
been made in Turkey and Greece. 
EU + 2 refers to EU Member States, Turkey and Norway. 
Price and purity of amphetamines: national mean values 
— minimum, maximum and interquartile range. Countries 
covered vary by indicator. Indexed trends are not available for 
methamphetamine.
Methamphetamine seized in Europe is mainly produced in 
Czechia and the border areas of neighbouring countries, 
although some producers have relocated their operations 
to the Netherlands. In Czechia, methamphetamine is 
produced mainly from pseudoephedrine, which is extracted 
from medicinal products. An important development, 
detected in the Netherlands in 2019, was the production 
of methamphetamine from BMK, with the involvement of 
Mexican nationals.
Data on seizures of precursors confirm the use of both 
scheduled and non-scheduled chemicals in the production 
of amphetamine and methamphetamine in the European 
Union (Table 1). The scheduling of APAAN (used to make 
BMK, the precursor of amphetamine) in late 2013 continues 
to have an impact, with seizures falling from 48 tonnes in 
2013 to 13.5 tonnes in 2018. Seizures of the alternative 
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chemical APAA have increased sharply in the last few 
years, tripling to over 30 tonnes in 2018 compared with 
2017. The forthcoming scheduling of APAA appears to 
have led to a preference for a new alternative substance, 
MAPA, of which 7 tonnes were seized in 2018. Seizures of 
glycidic derivatives of BMK, which can be readily converted 
to BMK, declined in 2018. The total quantity of precursors 
and alternative chemicals used for the production of 
amphetamine seized in the European Union reached an 
all-time high in 2018 at 73 tonnes, with 29 tonnes seized 
in the Netherlands, confirming the country’s central role in 
synthetic drug production in Europe.
In 2018 EU Member States reported 37 000 seizures of 
amphetamine, amounting to 8 tonnes, and there have 
been increases in each of the past three years (Figure 10). 
Methamphetamine seizures are far lower, with 9 000 
seizures reported in the European Union in 2018, amounting 
to 0.62 tonnes, with France (126 kilograms) and Czechia 
(106 kilograms) seizing the largest quantities (Figure 11). 
The number of seizures of methamphetamine has shown 
an overall upward trend since 2002, but with signs of recent 
stabilisation; the quantity seized has been relatively stable in 
EU countries since 2013.
In 2018 Turkey seized 5.7 tonnes of amphetamine. Almost all 
the amphetamine seized in Turkey was in the form of tablets 
(22.7 million tablets — over 87 % of the total estimated 
amount seized), including large quantities of ‘Captagon’ 
tablets containing amphetamine. Turkey also seized an 
exceptionally large quantity of methamphetamine in 2018 
(564 kilograms), an amount approaching that reported for 
the entire European Union (646 kilograms).
The average purity of amphetamine at retail level varied 
from 15 % to 64 % across Europe in 2018, with half the 
countries reporting an average purity between 19 % and 
34 %. Among those countries consistently providing data 
  Seizures Stopped shipments Totals
Scheduled/non-scheduled number quantity number quantity number quantity
MDMA and related substances
PMK (litres) 9 717 0 0 9 717
Safrole (litres) 2 175 0 0 2 175
Piperonal (kg) 2 29 5 950 7 979
Glycidic derivatives of PMK (kg) 109 15 741 0 0 109 15 741
Amphetamine and methamphetamine
BMK (litres) 22 9 253 0 0 29 9 253
Ephedrine bulk (kg) 14 39 0 0 14 39
Pseudoephedrine bulk (kg) 14 93 0 0 14 93
APAAN (kg) 13 13 535 0 0 13 13 535
Benzaldehyde (litres) 3 268 0 0 3 268
Benzylcyanide (litres) 3 9 060 0 0 3 9 060
PAA, phenylacetic acid (kg) 5 133 0 0 5 133
APAA (kg) 34 31 513 0 0 34 31 513
MAPA (kg) 19 7 027 0 0 19 7 027
Glycidic derivatives of BMK (kg) 11 2 340 0 0 11 2 340
Others
Acetic anhydride (litres) 12 15 667 8 8 888 20 24 555
4-anilino-N-phenethylpiperidine (ANPP) (kg) 1 0.6 0 0 1 0.6
N-phenethyl-4-piperidone (NPP) (kg) 0 0 1 3 1 3
2-bromo-4-methylpropiophenone (kg) 5 50 0 0 5 50
SUMMARY OF SEIZURES AND STOPPED SHIPMENTS OF EU SCHEDULED PRECURSORS AND NON-SCHEDULED CHEMICALS USED 
FOR SELECTED DRUGS PRODUCED IN THE EUROPEAN UNION, 2018
TABLE 1
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FIGURE 10 FIGURE 11
NUMBER OF AMPHETAMINE SEIZURES AND QUANTITY SEIZED: 
TRENDS AND 2018 OR MOST RECENT YEAR
NUMBER OF METAMPHETAMINE SEIZURES AND QUANTITY 
SEIZED: TRENDS AND 2018 OR MOST RECENT YEAR
Number of seizures Number of seizures
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on purity and price, the average purity of amphetamine 
has increased markedly over the past decade, albeit with 
some dips. Over the same period, the average price of 
amphetamine has decreased slightly. In 2018 the average 
purity of methamphetamine ranged from 21 % to 100 
%, with half of the countries reporting an average purity 
between 26 % and 81 %. It is not possible to analyse trends 
over time for methamphetamine. However, the overall 
average purity and price in 2018 were comparable to the 
values reported in 2008.
Data on the contents of amphetamines sold in Europe are 
also available from drug checking services. Their results 
indicated that samples presented as amphetamine had 
on average the lowest purity level and were more likely to 
contain pharmacologically active adulterants, compared 
with the other stimulant drugs tested (see Figure 12). In the 
period January-June 2019 a total of 652 samples presented 
as amphetamine were analysed by 11 European drug 
checking services. Three quarters (75 %) of these contained 
amphetamine and one or more pharmacologically active 
substance, whereas 20 % contained amphetamine as the 
sole pharmacologically active substance. The average purity 
of amphetamine samples submitted for testing in 2019 
was 37 %. The majority (56 %) of the samples presented as 
amphetamine were obtained through direct contact with a 
known supplier. Obtaining the drug through an acquaintance 
(12 %) was the next most common means of acquisition. 
Methamphetamine accounted for only 1 % of all samples 
submitted to drug checking services during the first half of 
2019. Fifty-four samples presented as methamphetamine 
were submitted for testing, 48 of them to Austrian and 
Spanish drug checking services.
Amphetamines use: stable, 
but with signs of increasing 
availability of methamphetamine  
It is estimated that 12.3 million adults in the European 
Union (aged 15-64), or 3.7 % of this age group, have used 
amphetamines at least once in their lifetime. Figures from 
the 26 countries that report a survey between 2014 and 
2018 suggest that 1.4 million (1.2 %) young adults (aged 
15-34) used amphetamines during the last year, with 
national prevalence estimates ranging from zero in Portugal 
to 3 % in Finland (Figure 13). The available data suggest 
that over the longer term, prevalence levels have been 
relatively stable in most countries. Of the countries that 
have provided new survey results since 2017 and reported 
confidence intervals, two reported higher estimates than 
FIGURE 12
AMPHETAMINE SAMPLES TESTED BY DRUG  
CHECKING SERVICES
Purity (% amphetamine)
Adulteration (1 011 ‘cocaine’ samples)
Amphetamine and 
inactive substances, 
24 %
(mean and range)
No amphetamine,  
5 %
Amphetamine
and active
substances, 71 %
1 37 99
24+71+5+x
Services providing samples
Energy
Control, 49 %
Trusted supplier, 56 %
Checkit, 18 %
Acquaintance, 11 %
Z6, 6 %
At the party, 8 %
DrogArt, 10 %
Darknet, 9 %
A-Clinic, 5 %
Street dealer, 5 %
Wedinos, 5 %
Other, 4 %
Neutravel, 3 %
Surface web, 1 %
49+18+10+6+5+5+3+4+x
56+11+9+8+5+4+2+5+x
Reported source of the drug
Samples were collected during the period January to June 2019. Data were 
provided by drug checking services in Austria (Checkit and Z6), Belgium 
(Modus Vivendi), Italy (Neutravel and SottoKassa), Luxembourg (PiPaPo), 
Slovenia (DrogArt), Spain (Energy Control and Ai Laket) and the United 
Kingdom (Wedinos) and a research project in Finland (A-Clinic Foundation).
Other, 4 %
No information, 5 %
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FIGURE 13
LAST YEAR PREVALENCE OF AMPHETAMINES USE AMONG YOUNG ADULTS (15-34): SELECTED TRENDS AND MOST RECENT DATA
Age ranges other than 15-34 are reported by Denmark, Estonia, United Kingdom and Norway (16-34), Sweden (17-34), Germany, France and Hungary (18-34).
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in the previous comparable survey, seven reported a stable 
trend and one a lower estimate.
A statistical analysis of trends in last year prevalence of use 
of amphetamines in young adults is only possible in a small 
number of countries and variations in patterns exist. Long-
term downward trends are observable in Denmark, Spain 
and the United Kingdom (Figure 13). 
Recent surveys in Czechia found prevalence levels of less 
than 1 %, trending downwards. In contrast, Norway has 
an upward trend since 2015, reporting 0.9 % for 2018. 
At higher levels of prevalence, Finland has a long-term 
upward trend reaching 3 % in 2018. In their 2018 survey, the 
Netherlands reported the prevalence of amphetamine use 
as 2.7 %, a decrease from 3.9 % in 2017. Both Germany and 
Poland report increases from previous surveys.
Methamphetamine in Europe now appears in both powder 
and crystalline form and is consumed by injecting or smoking 
by various sub-groups of people who use drugs, including 
problem drug users and people in the ‘chemsex’ scene. 
Analysis of municipal wastewater carried out in 2019 found 
that mass loads of amphetamine varied considerably across 
Europe, with the highest levels reported in cities in the north 
and east of Europe (Figure 14). Amphetamine was found at 
much lower levels in most cities in the south of Europe.
Of the 41 cities that have data for 2018 and 2019, 21 reported 
an increase, 9 a stable situation and 11 a decrease. Overall, the 
results from 11 cities with data from 2011 to 2019 showed a 
diverse picture, with increasing trends observed in most cities.
Wastewater analysis suggests that use of 
methamphetamine, generally low and historically 
concentrated in Czechia and Slovakia, now appears to 
be also present in other European countries (Figure 15). 
In 2018 and 2019, of the 42 cities that have data on 
methamphetamine in wastewater, 17 reported an increase, 
16 a stable situation and 9 a decrease.
Under embargo until 22 September 2020 at 10.00 Lisbon/11.00 CET
 Antwerp  Helsinki  Dortmund  Amsterdam  Oslo 
 Zagreb  Barcelona
mg/1 000 population/day
350
300
250
200
150
100
50
0
20152011 20162012 20172013 20182014 2019
32
European Drug Report 2020: Trends and Developments
FIGURE 14
FIGURE 15
AMPHETAMINE RESIDUES IN WASTEWATER IN SELECTED EUROPEAN CITIES: TRENDS AND MOST RECENT DATA 
METAMPHETAMINE RESIDUES IN WASTEWATER IN SELECTED EUROPEAN CITIES: TRENDS AND MOST RECENT DATA 
Mean daily amounts of amphetamine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year 
from 2011 to 2019. Source: Sewage Analysis Core Group Europe (SCORE).
Mean daily amounts of methamphetamine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year from 
2011 to 2019. Source: Sewage Analysis Core Group Europe (SCORE).
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Patterns of problematic 
amphetamines use vary 
considerably across countries
Problems related to long-term and injecting amphetamine 
use have, historically, been most evident in northern 
European countries, while methamphetamine problems 
have been concentrated in Czechia and Slovakia. A 2018 
estimate for Germany reported 0.2 % or 103 000 high-risk 
adult amphetamines users. In Finland, the estimated 
prevalence of high-risk amphetamine use was 0.7 % in 2017. 
In Czechia, high-risk methamphetamine use among adults 
(15-64) was estimated at 0.50 % in 2018 (corresponding 
to 33 500 users). This represents an increase from 20 900 
users in 2007, though numbers have been relatively stable 
in recent years. Users of amphetamines are likely to make 
up the majority of the estimated 2 234 (0.18 %) high-risk 
stimulant users reported by Latvia in 2017, down from 
6 540 (0.46 %) in 2010. In Slovakia, the prevalence derived 
from a treatment multiplier was estimated at 0.15 % in 
2018. The estimate for Cyprus was 0.03 % or 155 high-risk 
methamphetamine users in 2018. 
More than 20 000 clients entering specialised drug 
treatment in Europe in 2018 reported amphetamines as their 
primary drug, of whom about 10 000 were first-time clients. 
Amphetamine users account for at least 15 % of first-time 
treatment entrants in Bulgaria, Latvia, Poland and Finland. 
Treatment entrants reporting primary methamphetamine 
use are concentrated in Czechia, Germany, Slovakia, 
Poland and Turkey, which together account for 92 % of 
the 8 300 methamphetamine clients reported in 2018. 
Amphetamines are the drugs with the smallest gender 
gap, though women still represent only about one-quarter 
(26 %) of amphetamines clients. Considering route of 
administration, 15 % of all amphetamines entrants reported 
oral consumption of the drug, 52 % reported sniffing and 
17 % reported injecting.
AMPHETAMINES USERS ENTERING TREATMENT
Apart from the map, data are for all treatment entrants with amphetamines as primary drug. Data from Germany, Sweden and Norway relate to clients citing a 
stimulant other than cocaine as primary drug. United Kingdom data for 2018 do not include Northern Ireland.
Characteristics Frequency of use 
in the last month
Share of first-time entrants for all drugs 
(percent)
Route of administration
26 % 74 %
21Mean age at first use Mean use 4.4 days per week
Daily
2 to 6 days 
per week
Once a week 
or less
Not used in the 
last 30 days
30
Mean age at 
treatment 
entry
Previously 
treated entrants 
40 %
First-time 
entrants 60 %
6 900
10 200
29 %
28 %
12 %
31 %
40+60+x 17+15+15+52+1+x  Injecting, 17 % Smoking/inhaling, 15 % Eating/drinking, 15 % Sniffing, 52 % Other, 1 %
 >30
 15-30
 <15
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Health and social response options for amphetamines problems
  Brief interventions, referral to treatment programmes or harm reduction services can be offered when users seek help 
at emergency departments for problems related to intoxication or high-dose use.
  Stimulant injectors need regular access to needle and syringe programmes because they may inject more often than 
opioid users during the course of a binge.
  Outreach programmes may be necessary to deliver harm reduction interventions to stimulant users who would not 
otherwise access services.
  Treatment using psychosocial interventions can be effective for problematic stimulant use. There are no 
pharmacological treatments with good evidence of effectiveness in treating problematic stimulant users, but some 
drugs used to treat depression have been shown to help retain amphetamine users in treatment.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
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MDMA risks
prevention seizures
treatment
trends
use
MDMA is a synthetic drug that is chemically related to amphetamine and 
methamphetamine, but which differs to some extent in its effects. It is 
also known as ecstasy, when in tablet form or MD in crystal form. Data 
on MDMA from law enforcement and population surveys are augmented 
by findings from wastewater studies and drug checking services. This 
section also reviews the limited data available on hallucinogens and two 
anaesthetics, ketamine and gamma-hydroxybutyrate (GHB). 
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European production for a global 
MDMA market
Twenty-three active MDMA laboratories were reported to 
have been dismantled in the European Union in 2018, with 
most (20) detected in the Netherlands. The discovery of two 
MDMA laboratories in Spain and one in Sweden suggest 
a diversification of production locations may be under way 
however. The seized quantities of the MDMA precursor PMK 
(piperonyl methyl ketone) and non-scheduled chemicals 
for MDMA manufacture have decreased from 26 tonnes in 
2017 to under 16 tonnes in 2018. Despite the decrease in 
precursor seizures, there is no indication that the production 
of MDMA is going down, which may suggest an alternative 
trafficking route is being used. All seizures of PMK and most 
seizures of the glycidic derivatives of PMK in 2018 occurred 
in the Netherlands and Belgium.
Seizure reports from outside Europe, identified through 
the monitoring of open source information, and analysis 
of darknet market sales suggest that European producers 
play an important role in the global supply of MDMA. 
For example, darknet market monitoring data show that 
as well as facilitating direct sales to consumers, these 
markets are used by distributors across the globe to 
purchase MDMA produced in Europe. Analysis shows 
that transactions involving quantities of MDMA tablets 
indicative of the middle level of the market account for 
more than double the revenue of sales of retail-level 
quantities. In contrast, darknet cannabis and cocaine 
transactions are overwhelmingly at the retail level.
The number of reported MDMA seizures in the European 
Union has been on an upward trend since 2010. The quantity 
of MDMA seized is more often reported in number of tablets 
than by weight, and the estimated 4.7 million MDMA tablets 
reported seized in 2018 is the first decrease seen since 2015. 
However, this finding needs to be interpreted with caution 
due to the impact that a few large individual seizures can 
have on the number of tablets reported annually. Seizures 
of MDMA powder in the European Union increased from 
0.3 tonnes in 2016 to 2.2 tonnes in 2018. This increase is 
mainly due to seizures reported by Belgium, Poland, Bulgaria 
36 000
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and Spain — however, gaps in the data from the Netherlands 
prevents a more comprehensive analysis in this area. 
Large quantities of MDMA tablets were seized in Turkey 
in 2017 and 2018, amounting in both years to more than 
8 million tablets and exceeding the total amount seized in 
the European Union (Figure 16).
In 2018 the average drug content of MDMA tablets seized 
in Europe ranged from 39 to 188 milligrams MDMA 
per tablet, with half the countries reporting an average 
between 132 and 181 milligrams. Among those countries 
consistently reporting data between 2008 and 2017, the 
average drug content of MDMA tablets increased by 135 % 
over the period. While data limitations prevent the inclusion 
of 2018 in the analysis, average MDMA content remained 
stable compared with 2017. The average price of an MDMA 
tablet in 2018 ranged from EUR 4 to EUR 16, with half the 
countries reporting average prices of EUR 6 to EUR 10. 
Over the past decade, the average price of MDMA tablets 
has decreased slightly. 
Further data on MDMA dosage and purity are available from 
drug checking services operating in a number of European 
countries. These data, while not a representative sample, also 
point to the high MDMA content of tablets available in Europe 
and an increase in dosage over time. In the period January-
June 2019, samples presented as MDMA (both tablets and 
powders) were the second most common substance received 
for testing by European drug checking services. About 70 % 
of the 969 samples presented as MDMA were submitted 
for testing in drop-in centres and 25 % at music events. 
The average amount of MDMA per tablet tested in drug 
checking services was 180 milligrams, a slight increase on 
the 172 milligrams found during the same period in 2018, but 
much higher than the average of 102 milligrams found by the 
same network in 2012. Individual tablets with exceptionally 
high amounts of MDMA (in excess of 270 milligrams) were 
reported by services in five countries. High-purity MDMA in 
powder form was reported by all services, with an average 
purity of 88 %, compared with 72 % during the same period 
in 2018. Overall, samples presented to the services as MDMA 
were unlikely to contain any other pharmacologically active 
component, with such adulterants found in only 5 % of the 
powder samples and 6 % of the tablets tested (Figure 17). 
Caffeine was the most common adulterant in these samples, 
although the drug ketamine was detected in four MDMA 
samples. Half of the samples presented as MDMA were 
obtained through direct contact with a known supplier. 
Obtaining the drug through the darknet (13 %) was the next 
most common means of acquisition.
FIGURE 16
NUMBER OF MDMA SEIZURES (ALL FORMS) AND QUANTITY OF 
TABLETS SEIZED: TRENDS AND 2018 OR MOST RECENT YEAR
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FIGURE 17
MDMA SAMPLES TESTED BY DRUG CHECKING SERVICES 
BETWEEN JANUARY AND JUNE 2019
Purity of powder (% MDMA)MDMA contents of tablets
Adulteration (tablets 525 samples)
Adulteration (powder 414 samples)
MDMA and inactive 
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MDMA and inactive 
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No MDMA, 3 %
(mean and range)
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Reported source of the drug
Samples were collected during the period January to June 2019. Data were 
provided by drug checking services in Austria (Checkit and Z6), Belgium 
(Modus Vivendi), Italy (Neutravel and SottoKassa), Luxembourg (PiPaPo), 
Slovenia (DrogArt), Spain (Energy Control and Ai Laket) and the United 
Kingdom (Wedinos) and a research project in Finland (A-Clinic Foundation).
Others, 6 %
No information, 4 %
MDMA use: national variability
It is estimated that 13.6 million adults in the European 
Union (aged 15-64), or 4.1 % of this age group, have used 
MDMA/ecstasy at least once in their lifetime. Figures from 
the 27 countries that conducted surveys between 2014 
and 2018 suggest that 2.3 million young adults (15-34) 
used MDMA in the last year (1.9 % of this age group), with 
national estimates ranging from 0.2 % in Portugal and 
Romania to 6.9 % in the Netherlands (Figure 18). Prevalence 
estimates for those aged 15-24 years are higher, with 2.4 % 
(1.3 million) estimated to have used MDMA in the last year.
Until recently, MDMA prevalence in many countries had been on 
the decline from the peak levels seen in the early to mid-2000s. 
No overall trend emerges from the data available on recent 
MDMA use. Among the 12 countries that have provided new 
survey results since 2017 and reported confidence intervals, 
four reported higher estimates than in the previous comparable 
survey, and eight reported stable estimates.
Where data exist for a statistical analysis of trends in last 
year use of MDMA among young adults, some countries with 
longer-term trends now show stability (Figure 18). Following 
downward trends from peak rates at the start of the century, 
MDMA prevalence in Spain and the United Kingdom (England 
and Wales) is now stable, though at different levels. Spain 
reported a prevalence of 1.4 % in 2011 and 1.2 % in 2017, while 
the prevalence in the United Kingdom fluctuated between 2.4 % 
and 3.5 % over the period 2012-18, with a value of 3.1 % in 2018. 
Surveys in Finland show stability between 2014 and 2018; 2.5 % 
as opposed to 2.6 %, though an increase since earlier years. A 
recent stable trend is also observed in the Netherlands, where 
the prevalence of 6.9 % reported in 2018 is similar to the values 
reported since 2015. In contrast, Germany’s prevalence level 
more than doubled, from 1.3 % in 2015 to 2.8 % in 2018, while 
Denmark reported an increase to 1.5 % for 2017, from 0.7 % for 
2013. Norway observed an upward trend in between 2014 and 
2017 and reports 1.7 % for 2018, while annual surveys carried 
out in Czechia saw a decline from 3.6 % in 2014 to 1.6 % in 2018.
A 2019 multi-city analysis found the highest mass loads 
of MDMA in the wastewater in cities in Belgium, Germany 
and the Netherlands (Figure 19). Of the 42 cities that have 
data for 2018 and 2019, 23 reported an increase, 4 a stable 
situation and 15 a decrease. Looking at longer-term trends, 
in most cities with data for both 2011 and 2019 (12 cities), 
wastewater MDMA loads were higher in 2019 than in 2011; 
most initial increases were observed in the 2011-16 period, 
with further rises in the 2016-19 period in some cities.
Most of the health concerns around MDMA use centre on 
their possible toxicity, especially at high dose or toxicity from 
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FIGURE 18
FIGURE 19
LAST YEAR PREVALENCE OF MDMA USE AMONG YOUNG ADULTS (15-34): SELECTED TRENDS AND MOST RECENT DATA
MDMA RESIDUES IN WASTEWATER IN SELECTED EUROPEAN CITIES: TRENDS AND MOST RECENT DATA
Mean daily amounts of MDMA in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year from 2011 to 
2019. Source: Sewage Analysis Core Group Europe (SCORE).
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MDMA
adulterants sold as or mixed with MDMA. Correspondingly, 
MDMA use is rarely cited as a reason for entering specialised 
drug treatment in Europe. 
Ketamine, GHB and 
hallucinogens: more seized but 
use low and stable
A number of other substances with hallucinogenic, 
anaesthetic, dissociative or depressant properties are used 
in Europe: these include LSD, hallucinogenic mushrooms, 
ketamine and GHB (including its precursor GBL). 
LSD, a drug that has been uncommon in Europe for the last 
two decades, appears to be becoming more available. Over 
2 400 seizures of LSD (lysergic acid diethylamide) were 
reported in 2018, amounting to 1.06 million units. Most of 
these (93 %) were seized in Spain. The overall number of 
LSD seizures has more than doubled since 2010, although 
the quantity seized has fluctuated. Fifteen EU countries 
reported around 1 900 seizures of ketamine, amounting to 
an estimated 328 kilograms and 12 litres of the drug, most of 
which was accounted for by France (249 kilograms), Belgium 
(30 kilograms) and Spain (8 litres). In 2018 seizures of GHB 
(gamma-hydroxybutyrate) or its precursor GBL (gamma-
butyrolactone) were also reported by 13 EU countries, 
Norway and Turkey, with Norway accounting for over a third 
of the total number of seizures. The estimated 1 500 seizures 
of GHB and GBL amounted to almost 3.3 tonnes and 1 732 
litres. Belgium seized 92 % (3 tonnes) of the total quantity of 
powder, mainly as GHB, and Poland seized 64 % of the total 
quantity in liquid (1 100 litres), mainly as GBL.
The recreational use of ketamine and GHB (including 
GBL) has been reported among subgroups of drug users 
in Europe for the last two decades. National estimates, 
where they exist, of the prevalence of ketamine and GHB 
use in adult and school populations appear low. However, 
the Netherlands reports that ketamine has become a 
mainstream drug among young people in the nightlife 
scene, although use of the drug remains low in the general 
population. Last year prevalence of ketamine use among 
young adults (16-34) was estimated at 0.6 % in Denmark 
in 2017 and 1.7 % in the United Kingdom (England and 
Wales, 2018). In their 2018 survey, Norway reported last 
year prevalence of GHB use at 0.3 % for adults (16-64) and 
0.7 % for young adults (16-34); Poland reported last year 
prevalence of GHB use at 0.1 % for adults (15-64) and 0.2 % 
for young adults (15-34). 
The overall prevalence levels of LSD and hallucinogenic 
mushroom use in Europe have been generally low and stable 
for a number of years. Among young adults (15-34), national 
surveys report last year prevalence estimates equal to or less 
than 1 % for both substances in 2018 or most recent survey 
year, with the exception of Finland (2.0 %) and Estonia (1.6 %, 
16-34) for hallucinogenic mushrooms, and Finland (2.0 %), 
Estonia (1.7 %, 16-34) and Norway (1.3 %, 16-34) for LSD.
Health and social response options for problems related to drug use in recreational settings
  Prevention or harm reduction information material can be provided to young people in recreational settings. Peer 
educators disseminating this type of information may be seen as more credible. These activities can be supported 
by websites and apps providing more detailed information on drugs, alcohol and related harms, and tips on avoiding 
them. However, the evidence for behavioural change effects from these interventions is scarce.
  Environmental strategies have a better evidence base. This approach includes measures that target factors that 
promote excessive consumption (e.g. discounted drinks, loud music and poor serving practices) or that create safer 
spaces and venues (e.g. by reducing crowding, providing chill-out rooms and free water, serving food, enforcing rules 
on behaviour and access).
  Drug-checking services (sometimes called pill testing) enable individual drug users to have their synthetic drugs 
chemically analysed, providing information on the content of the samples as well as advice, and, in some cases, 
counselling or brief interventions. An understanding of the effectiveness of this approach in changing behaviours is still 
developing, but it may provide a valuable opportunity for engaging drug users, influencing consumption practices and 
for drug monitoring purposes.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
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NEW PSYCHOACTIVE 
SUBSTANCES risks
prevention seizures
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trends
use
The new psychoactive substance market comprises a large number of 
substances, with new compounds being introduced continually, at a 
rate of more than 50 new drugs per year since 2012. These substances 
are drawn from a broad range of drug types and are not controlled by 
international drug laws. They include stimulants, synthetic cannabinoids, 
benzodiazepines, opioids, hallucinogens and dissociatives. This section 
presents seizure and forensic data from law enforcement sources 
compiled by the EU Early Warning System on New Psychoactive 
Substances together with the findings of population surveys.
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New psychoactive substances 
Diversity of new psychoactive 
substances available
At the end of 2019 the EMCDDA was monitoring around 
790 new psychoactive substances, 53 of which were 
reported for the first time in Europe in 2019. This represents 
a decrease from the close to 100 new psychoactive 
substances introduced to the European market each year 
in 2014-15 (Figure 20). The decrease may reflect the results 
of sustained efforts to control new substances in Europe, 
as well as legal changes in source countries, such as China, 
to restrict production, including generic drug controls that 
cover chemical classes.
Despite the apparent decrease in the number of substances 
newly introduced to the European market each year, the 
catalogue of new psychoactive substances remains vast. 
Since 2015 approximately 400 previously reported new 
psychoactive substances have been detected each year 
(Figure 21). This illustrates the dynamic nature of this 
part of the drug market: substances may appear and 
then disappear rapidly, but the number of substances in 
circulation remains high.
Synthetic cannabinoids and 
cathinones dominate seizures of 
new psychoactive substances
The frequency and quantities of new psychoactive 
substances seized in Europe rose sharply until 2015. 
Since then, this trend seems to have reversed towards 
a stabilisation or slow decline, depending on the region. 
Even so, overall availability remains high. 
During 2018 law enforcement agencies from across Europe 
reported close to 64 800 seizures of new psychoactive 
substances to the EU Early Warning System. Of these, 
approximately 40 200 seizures were reported by EU Member 
States (Figure 22), a slight decrease compared with 2017.
In 2018 more than 5.6 tonnes of new synthetic psychoactive 
substances, mostly in the form of powders, was reported 
to the EU Early Warning System, 4.4 tonnes of which by 
Member States. In addition, 4 212 litres of liquids and 
1.6 million tablets and capsules were also found to contain 
new psychoactive substances. 
NUMBER AND CATEGORIES OF NEW PSYCHOACTIVE SUBSTANCES REPORTED TO THE EU EARLY WARNING SYSTEM  
FOR THE FIRST TIME, 2008-19
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NUMBER AND CATEGORIES OF SUBSTANCES DETECTED EACH YEAR, FOLLOWING THEIR FIRST DETECTION, 2008-18 
SEIZURES OF NEW PSYCHOACTIVE SUBSTANCES REPORTED TO THE EU EARLY WARNING SYSTEM: TRENDS IN TOTAL NUMBER 
OF SEIZURES (2008-18) AND BREAKDOWN OF NUMBER OF SEIZURES BY CATEGORY (EUROPEAN UNION) IN 2018 
FIGURE 21 
FIGURE 22
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In Europe, seizures of new psychoactive substances 
are typically dominated by synthetic cannabinoids and 
cathinones, which together accounted for 77 % of all 
seizures reported in 2018 (64 % for the EU Member 
States) (Figure 22). 
Products containing cannabinoids and cathinones, including 
herbal smoking mixtures and liquids for e-cigarettes are 
typically prepared from bulk powders. In recent years, 
there has been a decrease in the number and quantity of 
powders containing synthetic cannabinoids and cathinones 
seized in the European Union (Figure 23). For cannabinoids, 
this may reflect a decrease in local processing of herbal 
smoking mixtures. For cathinones, more complex factors 
may be at play since the apparent drop in the quantity of 
powders seized, compared with 2015 and 2016, occurs in 
the context of a small but increasing number of cathinone 
production sites being discovered in Europe. In 2018 a 
total of 50 kilograms of the cathinone precursor 2-bromo-
4-methylpropiophenone was seized within the European 
Union, while three laboratories were detected producing 
mephedrone (Spain, Netherlands, Poland), indicating the 
continued production of this drug within Europe.
SEIZURES OF SYNTHETIC CANNABINOIDS (LEFT) AND SYNTHETIC CATHINONES (RIGHT) REPORTED TO THE EU EARLY WARNING 
SYSTEM: TRENDS IN NUMBER OF SEIZURES AND QUANTITY SEIZED, 2008-18
FIGURE 23
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Fentanyl derivatives replaced by 
other new synthetic opioids
Synthetic opioids pose a very high risk of poisoning to 
consumers. Since 2009, 57 new synthetic opioids have been 
detected on Europe’s drug market — including eight reported 
for the first time in 2019. In 2019 only two of these opioids 
were fentanyl derivatives, which is a small proportion when 
compared with previous years (Figure 24). The remaining 
six opioids (2-fluoro-viminol, AP-237, 2-methyl-AP-237, 
piperidylthiambutene, furanyl UF-17 and isotonitazene) are 
all chemically different from fentanyl, despite posing similar 
concerns in respect to their toxicity.
In 2018 approximately 1 000 seizures of new opioids were 
reported to the EU Early Warning System (Figure 25). This 
amounted to approximately 9.3 kilograms of material, of 
which 7.3 kilograms was in the form of powders. Additionally, 
5.4 litres of liquids and 21 500 tablets and capsules 
(excluding tramadol) were also reported. The high potency 
of some synthetic opioids means that even small volumes 
could equate to many thousands of street doses.
Less commonly, new opioids have also been found in 
blotters and in herbal smoking mixtures. In these cases, 
there may be no indication that they contain potent opioids, 
posing a poisoning risk to those who may use them, 
particularly people with no existing tolerance to opioids. 
In 2018 more than half a kilogram of 4-anilino-N-
phenethylpiperidine (ANPP) was seized in France and 
a shipment of 3 kilograms of N-phenethyl-4-piperidone 
(NPP) was stopped in Belgium. Both are precursors for the 
manufacture of fentanyl and fentanyl derivatives.
New benzodiazepines associated 
with poisonings and deaths
Over the last few years reports have indicated an increase 
in the number, type and availability of new psychoactive 
substances belonging to the benzodiazepine class, which 
are not scheduled under international drug control laws. 
Some of these are sold as fake versions of commonly 
prescribed anti-anxiety medicines such as alprazolam 
(Xanax) and diazepam, making use of existing distribution 
networks in the illicit drug market. Others are sold online, 
sometimes under their own names, marketed as ‘legal’ 
versions of authorised medicines. 
The EMCDDA is currently monitoring 30 new 
benzodiazepines — 21 of which were first detected in 
Europe since 2015. In 2018 close to 4 700 seizures of new 
benzodiazepines were reported to the EU Early Warning 
NUMBER OF NEW SYNTHETIC OPIOIDS REPORTED TO THE EU 
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AND OTHER NEW SYNTHETIC OPIOIDS REPORTED TO THE EU 
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System, amounting to 1.4 million tablets, 1.3 litres of liquids 
and under 8 kilograms of powders. Within the United 
Kingdom, in Scotland, criminal groups are known to be 
involved in the large-scale illicit manufacture and distribution 
of fake benzodiazepine medicines. Typically made to look 
like 10-milligram diazepam tablets, and known as ‘street 
Valium’, these fakes often contain new or uncontrolled 
benzodiazepines. Substances that pose a high risk of severe 
poisoning have also occasionally been used, such as opioids 
and scopolamine.
In some countries, new benzodiazepines have been 
associated with harms, including an increased risk of 
overdose. In particular, etizolam, monitored by the EU 
Early Warning System since 2011, and more recently 
flualprazolam, first detected in 2018, have been associated 
with poisonings and deaths.
Use of new psychoactive 
substances remains low 
Since 2011 more than half of the European countries have 
reported national estimates of the use of new psychoactive 
substances (not including ketamine and GHB) in their 
general population surveys, although differences in methods 
and survey questions limit the comparability of the data. 
Among young adults (aged 15-34), estimates of last year 
prevalence of use of these substances ranged from zero 
in Norway to 1.9 % in Poland. Survey data on the use of 
mephedrone are available for the United Kingdom (England 
and Wales). In the most recent survey (2018), prevalence of 
last year use of this drug among 16- to 34-year-olds was 0.0 
%, down from 1.1 % in 2014. In Finland, the prevalence of use 
of cathinones in the last year among young adults (aged 15-
34) was 0.2 % in 2018. In their most recent surveys, last year 
use of synthetic cannabinoids among 15- to 34-year-olds 
ranged from 0.3 % in Spain and Lithuania to 0.6 % in Italy. 
New psychoactive substances represented 5 % of all 
drugs submitted for testing by individuals to drug checking 
services operating in 11 European countries during the 
first half of 2019. It should be noted that these results 
are not representative of the market as a whole. The 
most common substances detected among samples 
sold as new psychoactive substances were stimulants, 
primarily 4-MMC and 3-MMC (synthetic cathinones), 
followed by hallucinogens (1P-LSD and 4-AcO-DMT) 
and new benzodiazepines (etizolam and flualprazolam). 
However, new psychoactive substances were occasionally 
found as adulterants in samples submitted as MDMA. 
Over 100 samples sold as well-known benzodiazepines, 
such as diazepam, alprazolam or Z-drugs like zopiclone, 
contained etizolam, a benzodiazepine recently 
controlled internationally. 
While consumption levels of new psychoactive substances 
are low overall in Europe, in a 2016 EMCDDA study over 
two thirds of countries reported that their use by high-
risk drug users resulted in health concerns. In particular, 
the use of synthetic cathinones by opioid and stimulant 
injectors has been linked to health and social problems. 
In addition, the smoking of synthetic cannabinoids in 
marginalised populations, including homeless people and 
prisoners, has been identified as a problem in a number 
of European countries. Overall, few people currently enter 
treatment in Europe for problems associated with use of 
new psychoactive substances. 
New psychoactive substances 
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Health and social response options to problems related to use of new psychoactive substances
  Early-warning and risk assessment supported by multidisciplinary data, including the chemical identification  
of new substances from forensic and toxicology laboratory networks.
  Risk communication with authorities, professionals and users related to particularly harmful new substances, new 
formats of use, and emerging health and social threats.
  Supporting policy makers by providing scientific and evidence-based information on new psychoactive substances 
posing health and social threats.
  Inclusion of new substances into effective generic prevention programmes, with specific education and harm reduction 
messages targeted towards those already using drugs, or at risk of using new substances.
  Training and awareness-raising activities for relevant professionals, including staff of forensic and toxicology 
laboratories, health professionals and first responders, professionals in prevention, treatment and harm reduction 
services, in order to enhance their competencies in identifying and responding to use of new psychoactive substances.
  Development of clinical guidelines for the management of acute toxicity caused by new psychoactive substances.
  Multidisciplinary approaches and the linking up of different services are needed to engage vulnerable groups who 
may not come into contact with traditional services.
  Many of the health and social responses to new psychoactive substances are adaptations of programmes for 
‘established’ drugs. Responses have tended to target particular groups where problems have been observed.  
These vary by country but include recreational stimulant users, psychonauts, men who have sex with men, people 
avoiding drug tests, and high-risk drug users. There has also been a focus in many countries on strengthening legal 
responses and restricting the availability of these substances.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
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Europe’s drug  situation up to 2020: current and emerging threats
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HEROIN  
AND OTHER OPIOIDS
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Opioid use is a major contributor to the harms associated with drug use 
in Europe. Heroin is the most frequently used opioid, but others such as 
methadone, buprenorphine, tramadol and fentanyl derivatives are also 
available on the illicit market. This section relies on law enforcement data 
to describe the opioids market and on prevalence studies and data from 
specialised drug treatment centres for information on the prevalence and 
patterns of opioid use.  
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Heroin and other opioids
Quantity of heroin seized within 
the European Union doubles 
Afghanistan remains the world’s largest producer of illicit 
opium, the raw material for heroin, and most heroin found 
in Europe is thought to be manufactured in Afghanistan 
or in neighbouring Iran or Pakistan. Heroin enters Europe 
along four main trafficking routes, of which the Balkan route 
is considered the most important. A recent development is 
the emergence of trafficking through the Suez Canal and 
across the Mediterranean Sea. The discovery of laboratories 
producing heroin from morphine in Bulgaria, Czechia, 
Spain and the Netherlands in recent years, together with an 
increase in morphine and opium seizures suggests, however, 
that some heroin is now manufactured in the European 
Union. This may reflect suppliers seeking to reduce costs, 
as the heroin precursor chemical acetic anhydride is more 
expensive in opium-producing countries. 
In 2018 law enforcement agencies in the European Union 
seized almost 16 tonnes of acetic anhydride and a further 
9 tonnes was stopped before it entered the supply chain. 
These figures represent a large decrease compared with 
2017 (81 tonnes). Analysis of stopped shipments of acetic 
anhydride indicate that groups producing heroin outside the 
European Union attempt to obtain supplies from European 
chemical suppliers. 
A period of reduced heroin availability was observed 
in a number of European countries around 2010/11, 
accompanied by an overall drop in both numbers of 
seizures and quantities of heroin seized. Since then, 
seizures in the European Union have largely stabilised, 
with 37 000 seizures reported in both 2017 and 2018. 
However, the amount seized in the European Union in 
2018 increased to 9.7 tonnes, up from 5.2 tonnes in 
2017, mainly due to large individual seizures made in the 
port of Antwerp. Turkey continues to seize more heroin 
than all other European countries combined (Figure 26). 
Following a steep drop in seizures in the period 2014-16, 
from 12.8 to 5.6 tonnes, in 2017-18 Turkey seized around 
17 tonnes of heroin each year (17.4 and 17.8), the largest 
quantities for a decade. 
Among those countries consistently reporting price and 
purity data, indexed trends suggest that, following a sharp 
decrease between 2009 and 2011, heroin purity increased 
rapidly before stabilising in recent years. In contrast, the retail 
price of heroin declined between 2008 and 2014, and has 
been relatively stable since then. In 2018 half the countries 
reported a mean purity of heroin at retail level in the range 
18-30 % and a mean price in the range EUR 29-79 per gram. 
Although seizures of opioids other than heroin represent 
a small fraction of total opioid seizures, they have increased 
markedly in recent years. The non-heroin opioids most 
commonly seized include the medicinal opioids tramadol, 
buprenorphine and methadone (see Table 2). In 2018 the 
quantities of morphine, codeine and methadone seized 
were greater than in 2017, and seizure data support the 
concern that the interest in synthetic opioids of all types 
may be growing.
HEROIN
EU + 2 refers to EU Member States, Turkey and Norway.  
Price and purity of ‘brown heroin’: national mean values — minimum, 
maximum and interquartile range. Countries covered vary by indicator.
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FIGURE 26
NUMBER OF HEROIN SEIZURES AND QUANTITY SEIZED: 
TRENDS AND 2018 OR MOST RECENT YEAR
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countriesKilograms Litres Tablets Patches
Methadone 1 650 130.9 26.4 34 500  20
Buprenorphine 3 220 0.2  106 500  18
Tramadol 5 520 0.7  1 112 300  14
Fentanyl derivatives 930 6.2 0.1 19 800 587 13
Morphine 1 110 354.1 0.2 12 400  12
Opium 550 781.2    15
Codeine 510 0.3  28 400  12
Dihydrocodeine 7   500  3
Oxycodone 650 <0.1  15 200  8
TABLE 2
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Prevalence per 1 000 population aged 15-64 years (with uncertainty intervals)
PREVALENCE OF HIGH-RISK OPIOID USE PER 1 000 POPULATION AGED 15-64 YEARS, BY COUNTRY (MOST RECENT STUDIES)
FIGURE 27
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High-risk opioid use: continued 
decline of first-time heroin 
treatment entries 
The prevalence of high-risk opioid use among adults (15-64) 
is estimated at 0.4 % of the EU population, equivalent to 
1.3 million high-risk opioid users in 2018. At national level, 
prevalence estimates of high-risk opioid use range from 
less than 1 to more than 8 users per 1 000 population aged 
15-64 (Figure 27). The five most populous countries in 
the European Union (Germany, Spain, France, Italy, United 
Kingdom), account for three quarters (75 %) of this estimate. 
In 2018 use of opioids was reported as the main reason 
for entering specialised drug treatment by 143 000 clients, 
or 34 % of all those entering drug treatment in Europe. 
Of these, more than 27 000 were first-time entrants. Primary 
heroin users accounted for 77 % (almost 20 000 clients) 
of first-time primary opioid users entering treatment, a drop 
of 2 200 clients or 10 % compared with the previous year. 
According to the available trend data, the number of first-
time heroin clients has fallen by more than half from a peak 
observed in 2007. Between 2017 and 2018 the number 
of first-time treatment entrants for primary heroin use 
decreased in 18 countries out of the 29 with available data.
Synthetic opioids: national 
variation in substances used
Opioids other than heroin reported by treatment entrants 
include misused methadone, buprenorphine, fentanyl, 
codeine, morphine, tramadol and oxycodone. Overall, non-
heroin opioids account for 16 % of all clients citing an opioid 
as their main problem drug. In some countries, non-heroin 
opioids represent the most common form of opioid use 
among entrants to specialised treatment. Twenty European 
countries reported that more than 10 % of all opioid 
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HEROIN
Apart from trends, data are for all treatment entrants with heroin as primary drug. Data for Germany are for entrants with ‘opioids’ as primary drug. 
Trends in first-time entrants are based on 24 countries. Only countries with data for at least 11 of the 13 years are included in the trends graph. 
Missing values are interpolated from adjacent years. Due to changes in the flow of data at national level, data since 2014 for Italy are not comparable 
with earlier years. United Kingdom data for 2018 do not include Northern Ireland. 
 Italy  Spain  Germany  
 United Kingdom  Other countries
 Injecting, 34 %
 Smoking/inhaling, 47 %
 Eating/drinking, 3 %
 Sniffing, 15 %
 Other, 1 %
60 000
50 000
40 000
30 000
20 000
10 000
0
2006 2008 2010 2012 2014 2016 2018
Trends in first-time entrantsCharacteristics Frequency of use 
in the last month
Route of administration
20 % 80 %
24Mean age at first use Mean use 6 days per week
Daily
2 to 6 days 
per week
Once a week 
or less
Not used in the 
last 30 days
35Mean age at treatment entry
Previously 
treated entrants 
81 %
20 400
65 %
14 %
6 %
16 %
19+81+x 34+47+3+15+1+x
First-time 
entrants 19 %
86 400
Heroin users entering treatment
FIGURE 28
TREATMENT ENTRANTS CITING OPIOIDS AS PRIMARY DRUG: BY TYPE OF OPIOID (LEFT)  
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clients entering specialised services in 2018 presented 
for problems primarily related to opioids other than heroin 
(Figure 28). In Estonia, the majority of treatment entrants 
reporting an opioid as their primary drug were using fentanyl, 
while buprenorphine was the most cited primary opioid 
among treatment entrants in Finland. Buprenorphine misuse 
is reported by around 24 % of opioid clients in Czechia, with 
the misuse of methadone being reported by 23 % of opioid 
clients in Germany and 22 % in Denmark. Non-heroin opioids 
also account for a large share of opioid treatment clients 
in Poland, where 27 % of opioid clients report ‘kompot’ — 
heroin made from poppy straw — and in Cyprus, where 39 % 
report oxycodone. It should be noted that those entering 
treatment for problems relating to new psychoactive 
substances with opioid-like effects may be reported under 
the general heading of opioids. 
Health and social response options to problems related to use of opioids
  Pharmacological interventions, such as opioid substitution treatment, usually with methadone or buprenorphine. 
Heroin-assisted treatment may be useful for people who have not responded to other forms of opioid substitution 
treatment.
  Behavioural and psychosocial interventions to address psychological and social aspects of drug use include 
brief interventions, structured psychological therapies, motivational interventions, contingency management and 
behavioural couples therapy. They are often used in conjunction with pharmacological interventions.
  Residential rehabilitation involves living in a treatment facility and following a structured, care-planned programme 
of medical, therapeutic and other activities. This approach is suitable for clients with medium or high levels of need.
  Self-help and mutual aid groups teach cognitive, behavioural and self-management techniques without formal 
professional guidance.
  Recovery/reintegration support services, for example, offer employment and housing support.
  Effective long-term treatment of opioid dependence often requires multiple treatment episodes and combinations 
of responses. Harm reduction interventions, mental health and other services, addressing co-occurring mental and 
physical health problems, will also be important.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
Heroin and other opioids
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Injecting drug use continues to 
decline among new heroin clients 
Only 16 countries have estimates of the prevalence 
of injecting drug use since 2012, where they range from less 
than 1 to more than 10 cases per 1 000 population aged 
15-64. Opioids are reported as the main injected drugs in the 
majority (14) of these countries (Figure 29). 
Among first-time clients entering specialised drug treatment 
in 2018 with heroin as their primary drug, 24 % reported 
injecting as their main route of administration, down from 
43 % in 2006. In this group, levels of injecting vary between 
countries, from 9 % in Spain and Portugal to 90 % or more in 
Latvia. Injecting is reported as the main route of administration 
by less than 1 % of first-time cocaine clients and 21 % of 
first-time amphetamines clients. The overall picture for 
amphetamines, however, is influenced by Czechia, which 
accounts for more than 50 % of new amphetamines clients 
injecting the drug in Europe. Considering the three main 
injected drugs together, injecting as the main route of 
administration among first-time entrants to treatment in 
Europe has declined from 26 % in 2006 to 10 % in 2018 
(Figure 30).
INJECTING  
DRUG  
USE
Injecting drug use is more commonly 
associated with opioids, although in a 
few countries the injecting of stimulants 
such as amphetamines or cocaine is 
more prevalent. In this section, national 
studies on the prevalence of injecting 
drug use and data from specialised drug 
treatment centres are complemented 
by findings from a multicentre European 
study on drug residues in used syringes.   
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INJECTING DRUG USE: MOST RECENT ESTIMATES OF PREVALENCE OF INJECTING ANY DRUG IN THE LAST YEAR  
AND MAIN DRUG INJECTED
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0 2 4 6 8 10 12
Estonia (2015)
Latvia (2016)
Czechia (2018)
Lithuania (2016)
Finland (2012)
Luxembourg (2015)
Belgium (2015)
France (2017)
Norway (2017)
Croatia (2015)
Portugal (2015)
Hungary (2015)
Cyprus (2018)
Greece (2018)
Spain (2017)
Netherlands (2015)
Fentanyl
Heroin, amphetamines
Methamphetamine
Heroin
Buprenorphine
Heroin
Heroin
Heroin
Heroin
Heroin
Heroin
Heroin
Heroin
Heroin
Synthetic cathinones
Cocaine, heroin
30 
25 
20 
15 
10 
5 
0 
 Cocaine  Amphetamines  Heroin
20122006 2007 2008 20132009 20142010 20152011 2016 2017 2018
Percent
57
Injecting  drug  use
FIGURE 30
INJECTING AMONG FIRST-TIME TREATMENT  
ENTRANTS WITH HEROIN, COCAINE OR AMPHETAMINES  
AS PRIMARY DRUG: PERCENTAGE REPORTING INJECTING  
AS MAIN ROUTE OF ADMINISTRATION
Insights from syringe residue 
data: stimulant drugs 
commonly found
Data from drug treatment and high-risk drug use estimates 
can be complemented by findings from the European 
Syringe Collection and Analysis Project Enterprise (ESCAPE) 
network, which collates information on injected substances 
by analysing the residual content of used syringes. In 2019 
syringes were collected from the bins of street automatic 
injection kit dispensers and at harm reduction services in 
Amsterdam, Budapest, Cologne, Helsinki, Oslo, Paris and 
Vilnius. The contents of 1 180 used syringes were tested in 
seven laboratories. 
A high proportion of the syringes in six of the cities contained 
stimulants, with cocaine, amphetamines and synthetic 
cathinones often found (Figure 31); the exception was 
Vilnius, were only opioids (methadone or carfentanil) were 
found in the majority of syringes. A third of the syringes 
contained two or more drugs; the most frequent combination 
being a mix of stimulant and opioid.
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Circle area is proportional to percentage of syringes in each location in which a substance was detected. More than one substance may be detected in a single 
syringe. Study conducted in 2019. Source: European Syringe Collection and Analysis Project Enterprise (ESCAPE) network.
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DRUG RESIDUES IN USED SYRINGES IN SELECTED EUROPEAN CITIES, 2019
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Established drugs increase 
in emergency presentations
Hospital emergency data can provide an insight into acute 
drug-related harms and the public health impact of the use 
of drugs in Europe. Only a small number of countries, such 
as Czechia, Denmark, Spain, France and the Netherlands, 
report data on acute drug emergencies. Among these, the 
Netherlands has a multi-source monitoring system in place, 
which captures data from different medical services in 
eight regions plus first aid services operating at large-scale 
events at the national level. Data reported here is mainly 
from a sentinel station system without national coverage. 
The most common drugs involved in acute emergencies 
reported from this network of emergency centers in 
2018 were MDMA (46 %), cannabis (25 %), GHB (23 %), 
cocaine powder (16 %), ketamine (10 %) and the new 
psychoactive substance 4-fluoroamphetamine (4-FA, 
5 %). In 2018 the proportion of both MDMA and ketamine-
related presentations increased, while the proportion of 
presentations related to 4-FA, controlled in 2017, decreased. 
In Denmark, drug-related acute emergencies have 
shown an increasing trend, from 1 618 in 2009 to 2 618 
in 2018, with the overall increase primarily due to cases 
involving non-heroin opioids and stimulants. The number 
of emergencies related to heroin declined over the period, 
from 195 in 2010 to 130 in 2018. More recently, acute 
emergencies involving cocaine increased from 341 cases in 
2016 to 523 in 2018. Due to under-reporting, these are likely 
to be minimum figures. 
HOSPITAL 
EMERGENCIES
Hospital emergency data can provide 
an insight into acute drug-related harms 
and the public health impact of the use 
of drugs in Europe. Data on drug-related 
presentations to emergency departments 
collected by a number of countries allow 
some national-level analysis.  
A broader, albeit non-representative, 
European picture is afforded by the 
work of the Euro-DEN Plus network.
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Hospital emergencies
Cannabis was the drug most commonly involved in 
presentations in 2018, followed by cocaine and heroin 
(Figure 32). Seventeen percent of the drugs reported were 
prescription or over-the-counter medicines (most commonly 
benzodiazepines and opioids), 10 % were GHB/GBL, and 
4 % were new psychoactive substances. 
Differences in the drugs involved in emergency 
presentations between sites appear to reflect variations 
in hospital catchment area and local patterns of use. For 
example, emergencies involving amphetamines were 
most common in the north and east of Europe, whereas 
presentations related to cocaine were predominant in the 
south and west of Europe (Figure 32). 
The overall trend for the 14 Euro-DEN centres that have 
reported data for 2014-18 shows a rebound in the number 
of presentations related to heroin — mainly in London — and 
increases for powder cocaine and crack cocaine, cannabis, 
GHB/GBL and methamphetamine (Figure 33). The largest 
increases over this period in the number of presentations 
related to cocaine powder were reported in the centres 
in the north and west of Europe: Oslo, London, Dublin, as 
well as Mallorca. Meanwhile, London, Paris, and to a lesser 
extent Dublin reported the largest increases in presentations 
related to crack cocaine. During the same period, there was 
an overall decrease in presentations related to synthetic 
cathinones and an increase in those related to synthetic 
cannabinoids. The four hospitals in London and Oslo 
account for over half of the presentations to the 14 centres 
that have reported data since 2014. 
TRENDS IN THE NUMBER OF PRESENTATIONS RELATED 
TO SELECTED DRUGS TO THE 14 SENTINEL HOSPITALS THAT 
REPORTED DATA FOR 2014-18
FIGURE 33
Number of presentations
Data from the 14 Euro-DEN Plus sentinel hospitals reporting  
in each year from 2014 to 2018.
Source: European Drug Emergencies Network (Euro-DEN Plus). 
Drug-related acute toxicity presentations to 27 (sentinel) 
hospitals in 19 European countries are monitored by the 
European Drug Emergencies Network (Euro-DEN Plus). 
While the presentations seen in the sentinel hospitals 
may not reflect the national picture and this is not a 
representative data set, it does provide insight on trends in 
drug-related emergency presentations. In 2018 the hospitals 
recorded 9 134 presentations, most of whom were male 
(77 %). Almost three quarters of the presentations were 
brought to hospital by ambulance, with the majority (80 %) 
discharged within 12 hours. A small proportion needed to 
be admitted to critical care (6 %) or to a psychiatric ward 
(4 %). Some drugs were more associated than others 
with admission to critical care, such as GHB/GBL (16 %), 
methamphetamine (8 %) and MDMA (8 %). Among the 
sample, 30 in-hospital deaths were recorded, of which 
13 involved cocaine, 9 heroin and 11 other opioids. 
Most cases involved more than one drug. 
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Stimulant injecting linked  
to local HIV outbreaks
In 2018 an estimated 966 new HIV diagnoses attributable 
to injecting drug use were notified in the European Union. 
This represents a 4.8 %-share of all new HIV diagnoses 
for which the route of transmission is known, a proportion 
that has remained low and stable for the last decade. 
Most of these cases were males (82 %), typically 35 
years or older. Notifications of newly diagnosed HIV 
infections among people who inject drugs declined in most 
European countries between 2009 and 2018 (Figure 34). 
However, injecting drug use remains an important mode 
of transmission in some countries. In 2018, according 
to the data reported to the European Centre for Disease 
Prevention and Control, injecting drug use was linked to 
40 % of newly diagnosed HIV cases in Lithuania and 35 % 
in Latvia. Seroprevalence studies — based on blood samples 
— among people who inject drugs, conducted in Estonia, 
Greece, Latvia, Lithuania, Poland and Romania in 2017-18, 
found that more than 10 % of those tested were HIV-positive.
Localised HIV outbreaks have been documented among 
marginalised populations of people who inject drugs in 
Dublin (2014-15), Luxembourg (2014-16), Munich  
(2015-16), Lithuania (2016-17), Cologne (2018) and 
Glasgow (2015-19). These outbreaks have been sometimes 
associated with injection of stimulants, such as cocaine 
and synthetic cathinones. 
People who use drugs, particularly those 
who inject them, are at risk of contracting 
infections such as the hepatitis C virus 
(HCV) and the human immunodeficiency 
virus (HIV) through the sharing of drug 
use material. These infections typically 
cause chronic diseases that may result 
in severe health harms, including death. 
This section presents an overview of 
national data on new HIV diagnoses 
attributable to drug injecting along with 
serological data on HIV and HCV among 
national and sub-national samples 
of people who inject drugs.
DRUG-RELATED 
INFECTIOUS 
DISEASES
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Drug-related infectious diseases
Where the information was available, more than half of 
the new HIV diagnoses attributed to drug injecting in the 
European Union in 2018 were diagnosed late — that 
is, when the virus had already begun to damage the 
immune system — suggesting that opportunities for 
earlier intervention are being missed. Late HIV diagnosis is 
associated with delays in initiation of anti-retroviral therapy 
and increased morbidity and mortality. The policy of ‘test-
and-treat’ for HIV, whereby anti-retroviral therapy is started 
directly after an HIV diagnosis, can result in a reduction of 
transmission and is especially important among groups with 
higher-risk behaviours, such as people who inject drugs. 
Early diagnosis and initiation of anti-retroviral therapy offers 
those infected a normal life expectancy. Where data are 
available, EU countries are behind Sustainable Development 
Goals targets on HIV treatment and viral suppression among 
people who inject drugs, indicating that better linkage to care 
and adherence support is needed.
In 2018, 12 % of newly reported AIDS cases in the European 
Union, for which the route of transmission was known, were 
attributed to injecting drug use. These 327 injection-related 
AIDS notifications represent less than a quarter of the 
number reported a decade ago. 
HCV prevalence: national 
differences
Viral hepatitis, particularly infection caused by the hepatitis 
C virus (HCV), is highly prevalent among injecting drug users 
across Europe. For every 100 people infected with HCV, 
55 to 85 will develop chronic infection. This has important 
long-term consequences, as chronic HCV infection, often 
worsened by heavy alcohol use, will lead to increasing 
numbers of deaths and cases of severe liver disease, 
including cirrhosis and cancer, among an ageing population 
of high-risk drug users. 
The prevalence of antibodies to HCV among people who 
inject drugs, indicating present or past infection, is estimated 
from seroprevalence studies or routine diagnostic testing 
often offered in drug services. In 2017-18, HCV antibody 
prevalence in national samples of people who inject drugs 
varied from 16 % to 86 %, with 10 of the 16 countries with 
national data reporting rates in excess of 50 % (Figure 35). 
FIGURE 34
NEWLY DIAGNOSED HIV CASES RELATED TO INJECTING DRUG USE: OVERALL AND SELECTED TRENDS AND MOST RECENT DATA
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Patients who naturally clear the virus and those who are 
cured will, however, still test positive for HCV antibodies. 
In terms of burden of disease, it is important to identify 
individuals who remain chronically infected; they are at risk 
of cirrhosis and cancer, and can transmit the virus to others 
when sharing any injecting material that has been in contact 
with their blood. Among the countries reporting recent data 
on chronic infections among people who inject drugs, with 
a sample size equal to or greater than 100, the prevalence 
ranged from 27 % in the United Kingdom (England and 
Wales, 2018) to 55 % in Austria (Vienna, 2018).
Among people who inject drugs, hepatitis B virus (HBV) 
infection is less common than HCV infection, but still higher 
than in the general population, despite the availability of an 
effective vaccine. The presence of the HBV surface antigen 
indicates current infection, which may be acute or chronic. In 
the seven countries with national data for 2018, an average 
of 5.3 % (range: 0-17 %) of people who inject drugs were 
estimated to be currently infected with HBV.
Countries with 
national data
HCV ANTIBODY PREVALENCE AMONG PEOPLE WHO INJECT DRUGS: SEROPREVALENCE STUDIES AND DIAGNOSTIC TEST RESULTS 
WITH NATIONAL AND SUBNATIONAL COVERAGE, 2017-18
FIGURE 35
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Drug injection is a risk factor for other infectious diseases, 
and drug-related clusters of hepatitis A were reported in 
Czechia and Germany in 2016. In the United Kingdom, 
the number of notified group A Streptococcus and 
Staphyloccocus aureus cases associated with injecting drug 
use has increased, and wound botulism cases continue to 
be reported in Europe. 
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Overdose: a frequent cause 
of death among high-risk 
drug users
Drug use is a recognised cause of avoidable mortality 
among European adults. Overall, in Europe, people who 
use opioids are between 5 and 10 times more likely to die 
than their peers of the same age and gender. Overdose is 
one of the most frequent causes of deaths among people 
with drug problems. However, other causes of death 
indirectly related to drug use, such as HIV/AIDS and viral 
hepatitis, accidental injuries, violence including homicide 
and suicide, are also important causes of mortality in this 
group. Chronic pulmonary and liver conditions as well as 
cardiovascular problems are frequent and now account 
for an increased share of deaths among older and chronic 
drug users, who have long-term cycles of use, treatment, 
abstinence and relapse. 
Overdose data, especially the European cumulative total, 
must be interpreted with caution. Among the reasons for 
this are systematic under-reporting in some countries, 
differences in the ways toxicological examinations are 
conducted and registration processes that can result in 
reporting delays. Annual estimates therefore represent a 
provisional minimum value. 
It is estimated that at least 8 300 overdose deaths involving 
illicit drugs, primarily opioids, occurred in the European 
Union in 2018, representing a stable situation compared 
Drug use is a recognised cause of 
avoidable mortality among European 
adults. This section presents the most 
recent data on deaths attributed to 
acute drug toxicity (overdoses), a major 
contributor to the overall number of 
deaths related to drug use. The analysis 
covers both the overall numbers of 
deaths and the mortality rates. Trends in 
deaths related to heroin and cocaine are 
given a special focus. 
DRUG-RELATED 
DEATHS AND 
MORTALITY
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with 2017. This total rises to an estimated 9 200 deaths 
if Norway and Turkey are included, representing a slight 
decrease in relation to the revised estimate of 9 500 in 2017. 
The European analysis, however, is provisional and probably 
understates the actual number of deaths that occurred 
in 2018.
As in previous years, the United Kingdom (a third) and 
Germany together account for half of all reported overdose 
deaths in the European Union, Norway and Turkey. This figure 
needs to be interpreted in the context of both the size of the 
at-risk populations in these countries and under-reporting in 
some other countries.
Three quarters of those dying from overdose are male (76 %). 
The mean age of those who died in Europe continued to 
increase, reaching 41.7 years in 2018. This reflects the 
ageing nature of a large part of Europe’s opioid-using 
population, mainly in western Europe, who are at greatest 
risk of drug overdose death. In some countries, a proportion 
of opioid cases may be related to deaths involving opioids in 
the context of long-term pain management. 
Decreases in the numbers of deaths have been reported in 
Sweden, Estonia and Turkey. The declines in Estonia and 
Sweden are potentially related to decreased availability 
of fentanyl derivatives and a scaling-up of interventions, 
particularly the provision of take-home naloxone. The decline 
in overdose deaths in Turkey may be related to a number of 
factors, possibly including an increase in the coverage and 
effectiveness of the interventions available. 
Between 2012 and 2018 overdose deaths in the European 
Union increased in all age categories with the exception of 
those aged 20-29 (Figure 36). Deaths among the 50-plus 
age groups increased by 75 % overall, while deaths among 
younger age groups have generally been stable. Analysis of 
fatal overdoses reported by Turkey in 2018 shows a younger 
profile than the European Union average, with a mean age of 
32.5 years (Figure 37).
DRUG-INDUCED DEATHS 
Data refer to EU Member States, Turkey and Norway (EU + 2). Where 2018 data are not available, 2017 or otherwise most recent data are used.  
The latest data for the United Kingdom do not include Northern Ireland. 
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Drug-related deaths and mortality
Drug-induced mortality: northern 
Europe sees above-average rates 
The mortality rate due to overdoses in Europe in 2018 is 
estimated at 22.3 deaths per million population aged 15-64. 
The rate among males (35.1 cases per million males) is 
almost four times that among females (9.5 cases per million 
females). Males aged 35-44 are the most affected, with a 
mortality rate of 53.7 deaths per million, more than double 
the average seen for all ages, and more than three times the 
highest mortality rate in females (13.9 deaths per million 
females aged 35-44 years). 
National mortality rates and trends vary considerably and 
are influenced by factors such as prevalence and patterns of 
drug use, particularly injecting opioid use; risk and protective 
factors, such as the availability of treatment; and national 
practices of reporting, recording information and coding of 
overdose cases, including variable levels of under-reporting, 
in national mortality databases. Comparisons between 
countries should be made bearing in mind the national 
contexts and the limitations of some data. According to 
the latest data available, rates of over 40 deaths per million 
NUMBER OF DRUG-INDUCED DEATHS REPORTED IN THE 
EUROPEAN UNION IN 2012 AND 2018, OR MOST RECENT 
YEAR, BY AGE BAND
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FIGURE 36
AGE DISTRIBUTION OF DRUG-INDUCED DEATHS REPORTED IN 2018, OR MOST RECENT YEAR
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population were reported in eight northern European 
countries, with the highest rates reported in Sweden (81.5 
per million in 2018) and the United Kingdom (excluding 
Northern Ireland) (76.2 per million in 2017) (Figure 38). 
Scotland, in the United Kingdom, had the highest mortality 
rate in 2018, with 295 deaths per million adult population 
aged 15-64. 
Trends in heroin and cocaine-
related deaths 
Opioids, mainly heroin or its metabolites, often in 
combination with other substances, are present in the 
majority of fatal overdoses reported in Europe. Opioid-related 
deaths particularly predominate in the north of Europe — 
Austria, Denmark, Estonia, Finland, Ireland, Luxembourg, 
Norway, Sweden and the United Kingdom — and also in 
Bulgaria, Croatia and Romania, where around 9 out of 10 
overdose deaths involved some form of opioid. 
The number of heroin deaths increased in Portugal 
(29 deaths, a 93 % increase). As in 2017 Germany (405 
deaths in 2018, a 1 % decrease), Italy (155 deaths in 2018, 
a 5 % increase) and Turkey (205 deaths in 2018, a 3 % 
decrease) reported large numbers of heroin-related deaths 
in 2018. Sweden reported 98 heroin deaths in 2018. Austria 
reported an increase in deaths with morphine or heroin in 
the toxicology, from 77 in 2017 to 113 in 2018. 
Opioids other than heroin are also regularly mentioned in 
post mortem toxicology reports. These substances, primarily 
methadone, but also buprenorphine (Finland), fentanyl 
and its derivatives and tramadol, are associated with a 
substantial share of overdose deaths in some countries. 
Where post mortem toxicology is available on the presence 
of either fentanyl or fentanyl derivatives in fatal overdoses, 
declines have generally been observed in the most recent 
data. Countries reporting a decline include Germany (from 
157 deaths in 2017 to 59 in 2018), Estonia (from 86 in 
2017 to 12 in 2018) and Sweden (from 131 in 2017 to 30 in 
2018). Deaths linked to either fentanyl or fentanyl derivatives 
were stable in the United Kingdom (England and Wales; 106 
deaths registered in 2017 and 105 in 2018), while Finland 
reported an increase from 7 in 2017 to 14 in 2018.
FIGURE 38
DRUG-INDUCED MORTALITY RATES AMONG ADULTS (15-64): SELECTED TRENDS AND MOST RECENT DATA
Trends in the eight countries reporting the highest rates in 2018 or 2017 and overall European trend. UK data for 2017 do 
not include Northern Ireland. EU + 2 refers to EU Member States, Turkey and Norway. Due to methodological differences and 
potential under-reporting in some countries, comparisons between countries may not be valid. 
 >40
 10-40
 <10
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Health and social response options
Deaths
  These mainly focus on preventing the occurrence of overdoses and on improving the survival of those who overdose.
  Enrolling and retaining problem opioid users in OST and ensuring continuity between treatment in prisons and the 
community and at other transition points.
  Promoting overdose awareness, particularly around key risk periods and other risk factors, such as concurrent alcohol 
or benzodiazepine use.
  Ensuring opioid antagonist (naloxone) availability and promoting appropriate use by professionals responding to or 
intervening in drug overdoses.
  Education and training of drug users, peers and family members to identify overdoses and intervene with take-home 
naloxone while waiting for the ambulance to arrive.
  Provision of drug consumption rooms to support safer injecting.
Infectious diseases
  Providing opioid substitution treatment and other effective drug dependence treatment to people who inject drugs.
  Needle and syringe programmes providing sterile injection equipment to injectors.
  Vaccination against hepatitis A and B, tetanus and influenza, and also pneumococcal vaccine for HIV-positive individuals.
  Routine testing for HIV, HCV (HBV for unvaccinated) and other infections including tuberculosis.
  This needs to be linked to referral and treatment provision for those found to be infected, including the new direct-
acting antiviral treatments for HCV that are now available.
  Health promotion focused on safer injecting behaviour; sexual health, including condom use; and disease prevention, 
testing and treatment.
  Developing proactive, multi-component approaches that are adapted to user needs and local conditions.
These and other responses are further explained in the EMCDDA’s Health and Social Responses to Drug Problems: 
A European Guide supported by the online Best Practice Portal.
Stimulants such as cocaine, amphetamines, MDMA and 
cathinones are implicated in a smaller number of overdose 
deaths in Europe, although their significance varies by 
country. They are often found in combination with other 
substances. Similar to previous years, cocaine was present 
in more than half (53 %) of the drug-induced deaths reported 
in 2018 in Spain. Where data are available, an increase in 
cocaine-related deaths was reported in 2018 compared with 
2017 in Germany, Italy, Austria and Portugal. Similar year on 
year comparisons of the number of cocaine deaths cannot 
be made for France, Ireland and the United Kingdom. In 
these countries, the share of deaths related to the drug has 
increased in the most recent data; between 2016 and 2017 
in France and Ireland and among deaths registered in 2018 
in the United Kingdom.  
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Annex
National data for estimates of drug use prevalence 
including problem opioid use, substitution treatment, total 
number in treatment, treatment entry, injecting drug use, 
drug-induced deaths, drug-related infectious diseases, 
syringe distribution and seizures. The data are drawn from 
and are a subset of the EMCDDA Statistical Bulletin 2020, 
where notes and meta-data are available. The years to 
which data refer are indicated.
ANNEX
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OPIOIDS
TABLE A1
Country
Problem opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment 
entrants
% opioids clients injecting 
(main route of administration)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
Year of 
estimate
cases 
per 
1 000
% (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – – 21.1 
(2 322)
6.6 (269) 30.4 
(1 969)
13.7 (287) 11.4 (28) 13.8 (245) 16 179
Bulgaria – – 83.1 (987) 52.2 (144) 91.7 (705) 74.2 (710) 67.7 (88) 73.8 (516) 3 181
Czechia 2018 1.5-1.6 17.2 (751) 9.9 (188) 22.9 (525) 61.8 (443) 60.2 (112) 62.4 (311) 5 000
Denmark 2016 4.0-9.6 11 (565) 6.3 (151) 15.6 (404) 15 (85) 2.6 (4) 19.8 (80) 6 600
Germany 2016-17 2.4-3.1 17.3 
(6 977)
8.5 (1 972) – 22.3 
(1 067)
17.6 (246) – 79 400
Estonia – – 93.4 (271) 87.4 (76) 95.5 (150) 69.3 (187) 72 (54) 80.7 (121) 1 052
Ireland 2014 6.1-7.0 42.2 
(4 178)
18.1 (718) 60.2 
(3 312)
29.7 
(1 202)
19.7 (141) 32.2 
(1 032)
10 332
Greece 2018 1.6-2.4 55.1 
(2 036)
32.5 (494) 70.2 
(1 485)
26.5 (526) 19.5 (95) 29.1 (424) 9 162
Spain 2017 1.5-3.1 24.9 
(11 632)
12 (2 850) 39.4 
(8 404)
15.8 
(1 816)
8.4 (240) 17.5 
(1 457)
59 857
France 2017 4.5-5.9 24.8 
(11 935)
11.4 
(1 509)
39.7 
(7 519)
17.4 
(1 774)
10.2 (139) 20 (1 304) 178 665
Croatia 2015 2.5-4.0 – 21.2 (203) – – 30.9 (56) – 4 792
Italy 2018 6.5-7.2 42.6 
(16 445)
26.4 
(4 256)
54.1 
(12 189)
45.9 
(6 252)
32 (1 050) 50.4 
(5 202)
75 711
Cyprus 2018 1.6-2.7 24.4 (272) 13.3 (72) 38.6 (187) 36.3 (94) 44.1 (30) 34.1 (61) 257
Latvia 2017 4.7-7.0 49.4 (399) 28.7 (123) 72.8 (276) 82.8 (323) 73.8 (90) 86.9 (233) 690
Lithuania 2016 2.7-6.5 82.4 
(1 075)
50.7 (105) 89.1 (961) 83.3 (895) 77.1 (81) 84 (807) 1 275
Luxembourg 2015 4.5 51.6 (158) 35.4 (29) 59.6 (115) 46 (64) 34.8 (8) 48.5 (50) 1 142
Hungary 2010-11 0.4-0.5 2.6 (121) 1.2 (43) 6.7 (63) 34.7 (35) 7.9 (3) 52.6 (30) 650
Malta 2017 4.2-4.9 56.3 
(1 067)
19.5 (76) 65.8 (991) 54.2 (578) 30.3 (23) 56 (555) 729
Netherlands 
(1)
2012 1.1-1.5 11.5 
(1 262)
6.2 (402) 19.3 (860) 6.1 (39) 7.6 (13) 5.6 (26) 5 241
Austria 2017 6.1-6.5 47.5 
(1 966)
29.8 (548) 61.6 
(1 418)
34.7 (553) 21.1 (90) 39.6 (463) 19 216
Poland 2014 0.4-0.7 15.7 
(1 035)
6.2 (201) 25.7 (822) 53.5 (545) 36.7 (73) 58 (469) 2 797
Portugal 2015 3.8-7.6 37.1 
(1 214)
20.8 (379) 57.7 (835) 11 (127) 5.8 (21) 13.4 (106) 17 246
Romania 2017 0.8-2.9 24.6 
(1 048)
10.8 (314) 54 (734) 83.4 (859) 80.8 (253) 84.5 (606) 1 772
Slovenia 2018 3.1-4.3 79.5 (174) 44.9 (22) 89.3 (151) 39.1 (68) 13.6 (3) 42.4 (64) 3 301
Slovakia 2018 0.6-1.6 26.5 (805) 9.3 (115) 39.6 (676) 71.4 (566) 66.1 (74) 72.7 (487) 620
Finland 2017 6.9-8.6 48.5 (328) 35.5 (86) 55.8 (242) 77.3 (252) 75.6 (65) 77.9 (187) 3 329
Sweden (2) – – 23.6 
(10 005)
16.1 
(2 259)
27.7 
(7 363)
– – – 4 014
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Country
Problem opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment 
entrants
% opioids clients injecting 
(main route of administration)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
Year of 
estimate
cases 
per 
1 000
% (count) % (count) % (count) % (count) % (count) % (count) count
United 
Kingdom (3)
2014-15 8.3-8.7 49.7 
(55 687)
21.9 
(7 502)
62.1 
(48 081)
30.7 
(11 553)
15.6 (646) 32.7 
(10 884)
147 568
Turkey 2011 0.2-0.5 63 (7 141) 47.2 
(2 446)
76.3 
(4 695)
24.1 
(1 719)
14.1 (346) 29.2 
(1 373)
12 500
Norway (4) 2013 2.0-4.1 17 (1 010) 11.4 (309) 21.6 (701) – – – 7 762
European 
Union
– – 33.1 
(134 715)
15.4 
(25 106)
48.7 
(100 437)
31.6 
(30 960)
21.5 
(3 726)
34.6 
(25 720)
659 778
EU, Turkey 
and Norway
– – 33.7 
(142 866)
16.3 
(27 861)
49.1 
(105 833)
31.1 
(32 619)
20.6 
(4 072)
34.3 
(27 093)
680 040
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
Data on clients in substitution treatment are for 2018 or most recent year available: Luxembourg, 2017; Croatia, Denmark, France, Slovakia and Spain, 2016; 
Netherlands and Finland, 2015; Turkey, 2011. The number for Sweden does not represent all clients.
(1) Data for the number of clients in substitution treatment is not complete.
(2)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(3)  The high-risk opioid use estimate and the entrants into treatment data do not include Northern Ireland. Clients in substitution treatment relates  
to England and Wales.
(4) The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.
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COCAINE
TABLE A2
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adults  
(15-64)  
%
Last 12 
months, 
 young adults 
(15-34)  
%
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All clients First-time entrants
Previously 
treated 
entrants
% (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2018 – 2.9 25.4 
(2 804)
25.3 
(1 037)
24.7 
(1 600)
3.8 (97) 1.1 (11) 5.4 (77)
Bulgaria 2016 0.9 0.5 3.5 (41) 7.6 (21) 2.6 (20) 0 (0) 0 (0) 0 (0)
Czechia 2018 1.3 0.2 0.9 (38) 1 (19) 0.8 (18) 10.8 (4) 10.5 (2) 11.1 (2)
Denmark 2017 6.4 3.9 18.9 (971) 21.3 (511) 16.7 (432) 1.7 (16) 0.2 (1) 3.6 (15)
Germany 2018 4.1 2.4 6.5 (2 598) 6.6 (1 533) – 2 (36) 1.7 (18) –
Estonia 2018 5.0 2.8 0.3 (1) 1.1 (1) – – – –
Ireland 2015 7.8 2.9 22.1 
(2 186)
31.1 
(1 231)
15.9 (878) 0.8 (17) 0.5 (6) 1 (9)
Greece 2015 1.3 0.6 11.6 (429) 15.3 (233) 9.2 (194) 8.5 (36) 3.1 (7) 15 (29)
Spain 2017 10.3 2.8 43.1 
(20 168)
43.8 
(10 393)
42.3 
(9 025)
0.9 (179) 0.3 (36) 1.5 (138)
France 2017 5.6 3.2 10.8 
(5 182)
9.8 (1 300) 12.5 
(2 368)
8.2 (382) 2.7 (33) 12.2 (264)
Croatia 2015 2.7 1.6 – 3.2 (31) – – 3.2 (1) –
Italy 2017 6.9 1.7 32.7 
(12 641)
37.3 
(6 014)
29.4 
(6 627)
2.6 (294) 1.5 (79) 3.6 (215)
Cyprus 2016 1.4 0.4 17.8 (199) 15.9 (86) 20.2 (98) 2.6 (5) 2.4 (2) 3.1 (3)
Latvia 2015 1.5 1.2 0.5 (4) 0.7 (3) 0.3 (1) 0 (0) 0 (0) 0 (0)
Lithuania 2016 0.7 0.3 1.1 (15) 3.4 (7) 0.6 (7) 6.7 (1) 0 (0) 14.3 (1)
Luxembourg 2014 2.5 0.6 20.6 (63) 23.2 (19) 17.6 (34) 51.9 (27) 38.9 (7) 58.3 (14)
Hungary 2015 1.2 0.9 3 (143) 3.2 (113) 2.7 (25) 2.2 (3) 2.7 (3) 0 (0)
Malta 2013 0.5 – 26.8 (508) 49 (191) 21 (317) 16.5 (84) 3.7 (7) 24.3 (77)
Netherlands 2018 6.5 3.9 24.3 
(2 675)
20.8 
(1 357)
29.6 
(1 318)
0.4 (5) 0.1 (1) 0.6 (4)
Austria 2015 3.0 0.4 10.7 (443) 11.4 (210) 10.1 (233) 9.5 (41) 3.9 (8) 14.5 (33)
Poland 2018 0.7 0.5 2.6 (173) 2.2 (72) 3.1 (99) 1.2 (2) 1.4 (1) 1.1 (1)
Portugal 2016 1.2 0.3 19.9 (650) 21.8 (397) 17.5 (253) 2.4 (15) 1 (4) 4.6 (11)
Romania 2016 0.7 0.2 1.5 (64) 1.9 (55) 0.7 (9) 1.6 (1) 0 (0) 11.1 (1)
Slovenia 2018 2.7 1.8 7.3 (16) 18.4 (9) 4.1 (7) 25 (4) 0 (0) 57.1 (4)
Slovakia 2015 0.7 0.3 0.9 (28) 1.5 (18) 0.5 (9) – – –
Finland 2018 3.2 1.5 0.4 (3) 0.8 (2) 0.2 (1) 0 (0) 0 (0) 0 (0)
Sweden (1) 2017 – 2.5 1.7 (715) 3 (424) 0.7 (190) – – –
United 
Kingdom (2) 
2018 10.1 5.3 19.4 
(21 750)
25.4 
(8 712)
16.8 
(12 981)
1.7 (257) 0.4 (24) 2.7 (226)
Turkey 2017 0.2 0.1 2.9 (328) 3.2 (166) 2.6 (162) 0 (0) – 0 (0)
Norway 2018 5.1 2.3 1.9 (112) 2.8 (75) 1.1 (37) – – –
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 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adults  
(15-64)  
%
Last 12 
months, 
 young adults 
(15-34)  
%
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All clients First-time entrants
Previously 
treated 
entrants
% (count) % (count) % (count) % (count) % (count) % (count)
European 
Union
– 5.4 2.4 18.3 
(74 508)
20.9 
(33 999)
17.8 
(36 744)
2.4 
(1 506)
0.9 (251) 3.7 
(1 124)
EU, Turkey 
and Norway
– – – 17.7 
(74 948)
20 
(34 240)
17.1 
(36 943)
2.4 
(1 506)
0.9 (251) 3.7 
(1 124)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden.
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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AMPHETAMINES
TABLE A3
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Amphetamines clients as % of treatment entrants
% amphetamines clients injecting 
(main route of administration)
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
%  
(count)
% 
(count)
%  
(count)
%  
(count)
%  
(count)
% 
(count)
% 
 (count)
% 
(count)
Belgium 2018 – 0.8 9.2 
(1 015)
7 (285) 10.9 (706) 14.6 
(125)
10.1 (24) 16.4 (100)
Bulgaria 2016 1.5 1.8 7.1 (84) 20.3 (56) 3.3 (25) 1.2 (1) 0 (0) 0 (0)
Czechia 2018 2 0.5 50.1 
(2 185)
53.8 
(1 018)
46.9 
(1 074)
62.5 
(1 315)
57 (569) 68 (707)
Denmark 2017 7.0 1.4 6.1 (312) 5 (121) 7.1 (183) 3 (9) 2.5 (3) 3.5 (6)
Germany 2018 4.1 2.9 16.2 
(6 511)
14.5 
(3 387)
– 1.9 (79) 1.5 (33) –
Estonia 2018 6.1 2.1 3.8 (11) 6.9 (6) 2.5 (4) 50 (5) 66.7 (4) 33.3 (1)
Ireland 2015 4.1 0.6 0.6 (56) 0.9 (34) 0.3 (18) 7.4 (4) 5.9 (2) 11.1 (2)
Greece – – – 1.1 (41) 1.1 (16) 1.2 (25) 12.2 (5) 6.2 (1) 16 (4)
Spain 2017 4 0.9 1.5 (689) 1.7 (410) 1.2 (252) 1.2 (8) 1.5 (6) 0.8 (2)
France 2017 2.2 0.6 0.5 (220) 0.4 (50) 0.4 (80) 11.6 (20) 18.6 (8) 4.2 (3)
Croatia 2015 3.5 2.3 – 3.4 (33) – – 0 (0) –
Italy 2017 2.4 0.3 0.3 (102) 0.4 (67) 0.2 (35) 4.5 (4) 5.1 (3) 3.4 (1)
Cyprus 2016 0.5 0.1 6.6 (74) 5.7 (31) 8.5 (41) 7 (5) 10 (3) 5 (2)
Latvia 2015 1.9 0.7 17.5 
(141)
22.9 (98) 11.3 (43) 64.1 (84) 54.9 (50) 85 (34)
Lithuania 2016 1.2 0.5 2.8 (36) 9.2 (19) 1.3 (14) 16.7 (6) 15.8 (3) 21.4 (3)
Luxembourg 2014 1.6 0.1 0.3 (1) – – – – –
Hungary 2015 1.7 1.4 11.4 
(538)
11.2 
(394)
13 (122) 5.5 (29) 3.1 (12) 12.4 (15)
Malta 2013 0.3 – 0.3 (6) – 0.4 (6) 50 (3) – 50 (3)
Netherlands 2018 5.6 2.7 7.4 (817) 7.5 (487) 7.4 (330) 1.3 (4) 1 (2) 1.9 (2)
Austria 2015 2.2 0.9 5.6 (232) 7.1 (131) 4.4 (101) 1.4 (3) 0.8 (1) 2.1 (2)
Poland 2018 2.4 1.4 30.4 
(1 998)
33 
(1 074)
27.7 (885) 2.3 (45) 1.3 (14) 3.5 (30)
Portugal 2016 0.4 0.0 0.2 (5) 0.2 (3) 0.1 (2) 20 (1) 33.3 (1) 0 (0)
Romania 2016 0.3 0.1 0.5 (23) 0.7 (19) 0.3 (4) 0 (0) 0 (0) 0 (0)
Slovenia 2018 2.3 1.1 0.9 (2) 0 (0) 1.2 (2) 50 (1) 0 (0) 50 (1)
Slovakia 2015 1.4 0.8 40.8 
(1 241)
48.9 
(602)
34.8 (594) 28.1 
(331)
26.8 
(158)
30.5 (170)
Finland 2018 4.7 3.0 20.3 
(137)
17.8 (43) 21.7 (94) 73.5 
(100)
54.8 (23) 81.9 (77)
Sweden (1) 2017 – 1.2 6.6 
(2 778)
7.5 
(1 055)
4.8 (1 278) – – –
United Kingdom (2) 2018 8.6 1.0 2.1 
(2 305)
2.6 (880) 1.8 (1 416) 17.6 
(262)
11.1 (60) 21.4 (201)
Turkey 2017 0.0 – 7.8 (886) 12.2 
(631)
4.1 (255) 0.1 (1) – 0.4 (1)
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 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Amphetamines clients as % of treatment entrants
% amphetamines clients injecting 
(main route of administration)
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
%  
(count)
% 
(count)
%  
(count)
%  
(count)
%  
(count)
% 
(count)
% 
 (count)
% 
(count)
Norway 2018 3.5 0.9 12.9 
(770)
10.3 
(280)
15.1 (490) – – –
European Union – 3.7 1.2 5.3 
(21 560)
6.3 
(10 319)
3.6 (7 334) 17.2 
(2 449)
13.3 
(980)
26.6 
(1 366)
EU, Turkey and 
Norway
– – – 5.5 
(23 216)
6.6 
(11 230)
3.7 (8 079) 16.2 
(2 450)
12.3 
(980)
25.4 
(1 367)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.  
Data for Germany, Sweden and Norway refer to users of ‘stimulants other than cocaine’.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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MDMA
TABLE A4
Country Year of survey
Prevalence estimates
General population MDMA clients as % of treatment entrants
Lifetime, adults 
(15-64)
Last 12 months, 
young adults 
(15-34)
All entrants First-time entrants
Previously 
treated entrants
% % % (count)  % (count) % (count)
Belgium 2018 – 2.5 0.6 (62) 1 (43) 0.2 (16)
Bulgaria 2016 2.1 3.1 0.2 (2) 0.7 (2) 0 (0)
Czechia 2018 5.3 1.6 0.7 (30) 0.7 (14) 0.7 (15)
Denmark 2017 3.2 1.5 – – –
Germany 2018 3.9 2.8 – – –
Estonia 2018 5.4 2.5 0.3 (1) – 0.6 (1)
Ireland 2015 9.2 4.4 0.3 (32) 0.5 (18) 0.2 (12)
Greece 2015 0.6 0.4 0.2 (6) 0.3 (4) 0.1 (2)
Spain 2017 3.6 1.2 0.1 (68) 0.2 (56) 0 (10)
France 2017 3.9 1.3 0.3 (168) 0.5 (62) 0.2 (46)
Croatia 2015 3.0 1.4 – 0.8 (8) –
Italy 2017 2.7 0.8 0.1 (56) 0.1 (24) 0.1 (32)
Cyprus 2016 1.1 0.3 0.2 (2) 0.2 (1) 0.2 (1)
Latvia 2015 2.4 0.8 0.4 (3) 0.2 (1) 0.5 (2)
Lithuania 2016 1.7 1.0 0.5 (6) 1 (2) 0.4 (4)
Luxembourg 2014 1.9 0.4 0.3 (1) – 0.5 (1)
Hungary 2015 4.0 2.1 2.3 (110) 2.1 (75) 3.3 (31)
Malta 2013 0.7 – 0.9 (17) – 1.1 (17)
Netherlands 2018 10.3 6.9 0.7 (80) 1 (67) 0.3 (13)
Austria 2015 2.9 1.1 1 (42) 1.3 (24) 0.8 (18)
Poland 2018 1.0 0.5 0.3 (23) 0.6 (18) 0.2 (5)
Portugal 2016 0.7 0.2 0.2 (7) 0.3 (6) 0.1 (1)
Romania 2016 0.5 0.2 1.3 (55) 1.8 (52) 0.2 (3)
Slovenia 2018 2.9 1.3 0.5 (1) 2 (1) 0 (0)
Slovakia 2015 3.1 1.2 0.4 (13) 0.6 (8) 0.2 (4)
Finland 2018 5.0 2.6 0 (0) 0 (0) 0 (0)
Sweden 2017 – 2.0 – – –
United Kingdom (1) 2018 9.1 3.1 0.5 (555) 1.2 (396) 0.2 (156)
Turkey 2017 0.4 0.2 1.5 (172) 2.3 (118) 0.9 (54)
Norway 2018 3.6 1.7 – – –
European Union – 4.1 1.9 0.3 (1 340) 0.5 (882) 0.2 (390)
EU, Turkey and Norway – – – 0.4 (1 512) 0.6 (1 000) 0.2 (444)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1) Entrants into treatment do not include Northern Ireland.
Under embargo until 22 September 2020 at 10.00 Lisbon/11.00 CET
79
CANNABIS
TABLE A5
Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cannabis clients as % of treatment entrants
Lifetime, adults 
(15-64)
Last 12 months, 
young adults 
(15-34)
All entrants First-time entrants
Previously 
treated entrants
% % % (count) % (count) % (count)
Belgium 2018 22.6 13.6 34.6 (3 808) 51 (2 090) 24.4 (1 579)
Bulgaria 2016 8.3 10.3 2.2 (26) 4.3 (12) 1.7 (13)
Czechia 2018 26.2 16.6 25 (1 092) 29.1 (551) 21.9 (502)
Denmark 2017 38.4 15.4 60.6 (3 109) 64.1 (1 540) 57.2 (1 482)
Germany 2018 28.2 16.9 57.9 (23 301) 68.3 (15 895) –
Estonia 2018 24.5 16.6 1 (3) 2.3 (2) 0.6 (1)
Ireland 2015 27.9 13.8 23 (2 276) 38 (1 503) 11.6 (637)
Greece 2015 11.0 4.5 28.1 (1 038) 47.7 (725) 14.6 (308)
Spain 2017 35.2 18.3 27.6 (12 932) 38.4 (9 122) 15.5 (3 314)
France 2017 44.8 21.8 59.8 (28 818) 74.4 (9 868) 42.9 (8 124)
Croatia 2015 19.4 16.0 – 62.9 (602) –
Italy 2017 32.7 20.9 22 (8 514) 32.4 (5 217) 14.6 (3 297)
Cyprus 2016 12.1 4.3 50.7 (566) 64.8 (351) 32 (155)
Latvia 2015 9.8 10.0 24 (194) 36 (154) 10.6 (40)
Lithuania 2016 10.8 6.0 5.1 (66) 19.3 (40) 2.2 (24)
Luxembourg 2014 23.3 9.8 25.8 (79) 39 (32) 21.2 (41)
Hungary 2015 7.4 3.5 67.4 (3 174) 72.4 (2 539) 48.9 (458)
Malta 2013 4.3 – 13.2 (251) 26.9 (105) 9.7 (146)
Netherlands 2018 28.6 17.1 47.3 (5 202) 55.5 (3 625) 35.4 (1 577)
Austria 2015 23.6 14.1 33 (1 367) 48.6 (895) 20.5 (472)
Poland 2018 12.1 7.8 31.5 (2 074) 39.5 (1 286) 23.2 (743)
Portugal 2016 11.0 8.0 40 (1 309) 53.7 (980) 22.8 (329)
Romania 2016 5.8 5.8 54.4 (2 320) 68.9 (2 003) 23.3 (317)
Slovenia 2018 20.7 12.3 6.8 (15) 26.5 (13) 1.2 (2)
Slovakia 2015 15.8 9.3 21.2 (643) 31.2 (384) 13.8 (235)
Finland 2018 25.6 15.5 18.3 (124) 32.2 (78) 10.6 (46)
Sweden (1) 2018 16.7 7.9 10.7 (4 537) 14.4 (2 029) 7.1 (1 875)
United Kingdom (2) 2018 29.0 13.4 22.4 (25 103) 42.7 (14 647) 13.4 (10 375)
Turkey 2017 2.7 1.8 8.3 (941) 12.9 (668) 4.4 (273)
Norway 2018 23.6 9.6 30.1 (1 795) 39.4 (1 071) 22.3 (724)
European Union – 27.2 15.0 32.4 (131 941) 46.8 (76 288) 17.5 (36 092)
EU, Turkey and Norway – – – 31.7 (134 677) 45.7 (78 027) 17.2 (37 089)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, Sweden, United Kingdom and Norway; 18-65 for Malta. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture.
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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OTHER INDICATORS
TABLE A6
Country Year
Drug-induced deaths HIV 
diagnoses 
related to 
injecting drug 
use (ECDC)
Injecting drug use estimate Syringes 
distributed 
through 
specialised 
programmesAll ages Aged 15-64
Count
Cases per 
million 
population 
(count)
Cases per 
million 
population  
(count)
Year of 
estimate
Cases per 
1 000 
population
Count
Belgium 2014 61 8 (60) 1.1 (12) 2015 2.3-4.6 1 228 681
Bulgaria 2018 24 5 (21) 5.0 (35) – – 25 151
Czechia 2018 39 5 (36) 0.8 (8) 2018 5.8-6.0 6 932 269
Denmark 2017 238 52 (191) 1.0 (6) – – –
Germany (1) 2018 1 276 21 (1 120) 1.7 (140) – – –
Estonia 2018 39 43 (36) 18.2 (24) 2015 9.0-11.3 1 680 531
Ireland 2017 235 72 (227) 2.7 (13) – – 488 755
Greece 2017 62 – (–) 9.9 (106) 2018 0.4-0.7 245 860
Spain (2) 2017 437 14 (437) 1.6 (74) 2017 0.3-2.6 1 603 551
France (3) 2016 465 9 (391) 0.9 (61) 2017 2.6-3.3 11 998 221
Croatia (2) 2018 85 30 (80) 0.0 (0) 2015 1.8-2.9 244 299
Italy 2018 334 9 (332) 1.8 (106) – – –
Cyprus 2018 12 20 (12) 1.2 (1) 2018 0.4-0.8 243
Latvia 2018 20 16 (20) 37.7 (73) 2016 5.3-6.8 951 063
Lithuania 2018 59 32 (59) 19.6 (55) 2016 4.4-4.9 241 953
Luxembourg 2018 4 10 (4) 6.6 (4) 2015 3.8 492 704
Hungary 2018 33 4 (28) 0.1 (1) 2015 1.0 83 341
Malta 2017 5 16 (5) 0.0 (0) – – 275 969
Netherlands 2018 224 18 (206) 0.1 (2) 2015 0.07-0.09 –
Austria 2018 184 31 (184) 1.4 (12) – – 6 234 094
Poland 2017 202 7 (168) 0.5 (20) – – 129 681
Portugal 2017 51 6 (43) 2.0 (21) 2015 1.0-4.5 1 300 134
Romania (4) 2018 26 2 (26) 3.5 (68) – – 896 397
Slovenia 2018 59 41 (55) 0.0 (0) – – 591 080
Slovakia 2018 32 8 (30) 0.2 (1) – – 425 880
Finland 2018 261 72 (248) 1.1 (6) 2012 4.1-6.7 5 992 811
Sweden 2018 566 81 (515) 2.3 (23) – – 607 195
United Kingdom (5) 2017 3 284 76 (3 126) 1.4 (94) – – –
Turkey 2018 657 12 (637) 0.3 (24) – – –
Norway 2017 247 66 (229) 1.1 (6) 2017 2.0-2.6 3 000 000
European Union – 8 317 23.7 (7 660) 1.9 (966) – – –
EU, Turkey and Norway – 9 221 22.3 (8 526) 1.7 (996) – – –
In some cases, the age band is not specified, and these cases were not included in the calculations of mortality rate referring to the population aged 15-64:  
Portugal (1), Greece (62) and Turkey (14). 
(1) For ‘Drug-induced deaths (aged 15-64)’, the data for 2017 were used (147 cases without information on age). 
(2) Syringes distributed through specialised programmes refer to 2017.
(3) Syringes distributed through specialised programmes refer to 2016.
(4) Drug-induced deaths data with sub-national coverage: 3 counties out of 42 recorded DRD cases (Bucharest, Arad and Ilfov).
(5)  Drug-induced deaths data do not include Northern Ireland. Syringe data: England, no data; Wales 2 658 586; Scotland 4 401 387  
and Northern Ireland 337 390 both in 2017.
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SEIZURES
TABLE A7
Country
Heroin Cocaine Amphetamines MDMA, MDA, MDEA
Quantity 
seized
Number 
of 
seizures
Quantity 
seized
Number 
of 
seizures
Quantity 
seized
Number 
of 
seizures
Quantity seized
Number 
of 
seizures
kg count kg count kg count tablets (kg) count
Belgium 4 537 1 762 53 032 5 646 75 3 109 225 908 (587) 2 462
Bulgaria 1 033 43 22 29 91 94 5 054 (320) 45
Czechia 1 110 24 297 108 2 053 32 591 (9) 577
Denmark 38 427 151 4 786 379 2 080 18 320 (4) 722
Germany 298 – 8 166 – 1 784 – 693 668 (–) –
Estonia <0.1 7 4 164 22 472 – (8) 275
Ireland – 313 – 608 – 90 – (–) 304
Greece 207 2 388 166 766 782 12 62 762 (5) 82
Spain 251 8 058 48 453 45 583 413 4 725 337 904 (293) 4 084
France 1 115 4 103 16 357 12 578 334 615 1 783 480 (–) 1 048
Croatia 5 146 109 455 37 981 – (12) 642
Italy 975 2 236 3 623 7 995 18 177 23 176 (21) 297
Cyprus <0.1 9 5 129 1 105 939 (0) 15
Latvia <0.1 40 5 91 55 487 14 967 (3) 352
Lithuania 3 157 14 99 43 318 – (17) 167
Luxembourg 3 75 347 215 1.9 11 1 564 (–) 20
Hungary 35 49 25 303 22 1 153 43 984 (1) 792
Malta 5 20 188 166 0.004 1 369 (0) 83
Netherlands (1) 354 – 40 134 – 7 – – (472) –
Austria 76 1 115 75 1 810 85 1 759 83 037 (12) 1 174
Poland 9 3 277 2 1 354 34 218 442 (408) –
Portugal 27 225 5 541 501 0.4 52 4 145 (19) 186
Romania 5 264 35 358 3 165 53 072 (1) 819
Slovenia 11 286 12 277 6 242 – (–) 63
Slovakia 0.6 41 1 32 4 661 – (–) 74
Finland 0.1 76 10 340 203 2 456 219 352 (–) 839
Sweden 75 780 544 3 995 1 052 6 974 147 792 (22) 2 171
United Kingdom 617 10 868 3 469 19 451 1 668 3 682 713 896 (1) 3 630
Turkey 18 531 18 298 1 509 3 519 6 273 15 528 8 409 892 (–) 9 758
Norway 50 781 98 1 862 418 6 711 60 400 (11) 1 366
European Union 9 681 36 610 180 787 110 196 8 549 46 349 4 684 422 (2 217) 24 443
EU, Turkey and Norway 28 262 55 689 182 394 115 577 15 240 68 588 13 154 714 (2 228) 35 567
All data are for 2018 or most recent year.
(1)  Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures.  
Cocaine seizures represent the majority of large seizures
Annex | National data tables 
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Country
Cannabis resin Herbal cannabis Cannabis plants
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
kg count kg count plants (kg) count
Belgium 108 6 889 17 290 28 801 422 261 (–) 1 006
Bulgaria 2 21 986 85 24 244 (108 509) 147
Czechia 3 189 948 5 779 28 334 (–) 441
Denmark 8 956 18 715 293 1 803 17 840 (272) 480
Germany 1 295 – 7 731 – 101 598 (–) –
Estonia 110 48 72 707 – (20) 40
Ireland – 176 – 1 352 – (–) 112
Greece 7 388 291 12 812 9 198 50 597 (–) 635
Spain 436 963 167 530 37 220 143 087 981 148 (–) 2 986
France 85 400 76 227 29 800 30 175 138 564 (–) 462
Croatia 50 326 4 687 7 388 3 614 (–) 132
Italy 78 522 9 661 39 178 10 432 430 277 (–) 1 262
Cyprus 1 28 319 997 301 (–) 21
Latvia 133 57 41 866 – (108) 46
Lithuania 389 75 168 606 – (–) –
Luxembourg 181 434 35 647 34 (–) 9
Hungary 20 164 868 3 492 4 769 (–) 167
Malta 17 366 22 594.6 171 2 (–) 2
Netherlands (1) 7 288 – 3 002 – 516 418 (–) –
Austria 111 1 077 1 382 16 029 24 571 (–) 565
Poland 8 316 26 4 260 149 118 781 (–) 10
Portugal 4 170 1 774 138 300 8 706 (–) 139
Romania 8 200 266 3 354 – (28) 87
Slovenia 20 107 838 3 768 13 594 (–) 218
Slovakia 1 26 144 1 115 2 299 (–) 31
Finland 54 280 344 1 040 13 085 (–) 1 073
Sweden 2 709 16 280 960 7 166 – (–) –
United Kingdom 8 470 11 876 29 533 101 744 372 207 (–) 8 382
Turkey 31 473 13 798 49 232 51 374 – (–) 2 812
Norway 2 658 6 771 354 3 908 – (–) –
European Union 668 032 318 273 193 909 411 873 3 273 244 (108 935) 20 660
EU, Turkey and Norway 702 163 338 842 243 495 467 155 3 273 244 (108 935) 23 472
All data are for 2018 or most recent year.
(1) Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures. 
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European Drug Report: Trends and Developments
The Trends and Developments report, of which the Key 
Issues is a selected summary, presents a top-level overview 
of the drug phenomenon in Europe focused on illicit drug 
use, related health harms and drug supply. 
emcdda.europa.eu/edr2020
EMCDDA Publications 
In addition to the yearly European Drug Report, the EMCDDA 
publishes Health and Social Responses to Drug Use: A 
European Guide and, together with Europol, the European 
Drug Markets Report, alongside a wide range of detailed 
reports across the full spectrum of drugs issues. 
emcdda.europa.eu/publications
Best Practice
The Best Practice Portal provides practical and reliable 
information on what works (and what doesn't) in the 
areas of prevention, treatment, harm reduction and 
social reintegration. It will help you identify tried and 
tested interventions quickly, allocate resources to what's 
effective, and improve interventions applying tools, 
standards and guidelines.
emcdda.europa.eu/best-practice
Statistical Bulletin
The annual Statistical Bulletin contains the most recent 
available data on the drug situation in Europe provided 
by the Member States. These datasets underpin the 
analysis presented in the European Drug Report. All data 
may be viewed interactively on screen and downloaded 
in Excel format.
emcdda.europa.eu/data/
Topics
Hub pages and the A-Z index help you find EMCDDA content 
by topic. 
emcdda.europa.eu/topics
Document Library
The EMCDDA Document Library gives you access to 
documents related to the agency or collected by it in its 
work. There you can access publications by international and 
national organisations, scientific articles by EMCDDA staff, 
material published by other institutions of the European 
Union and other material acquired by the agency.
emcdda.europa.eu/document-library
EMCDDA 
RESOURCES
For in-depth information on illicit drugs consult 
EMCDDA publications and online resources.
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 Getting in touch with the EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can fi nd the address of the centre nearest you at: 
https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
– by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for 
these calls),
– at the following standard number: +32 22999696 or
– by email via: https://europa.eu/european-union/contact_en
Finding information about the EU
Online
Information about the European Union in all the offi  cial languages of the 
EU is available on the Europa website at: https://europa.eu/european-
union/index_en
EU publications
You can download or order free and priced EU publications at: 
https://publications.europa.eu/en/publications. Multiple copies of free 
publications may be obtained by contacting Europe Direct or your local 
information centre (see https://europa.eu/european-union/contact_en).
EU law and related documents
For access to legal information from the EU, including all EU law since 
1952 in all the offi  cial language versions, go to EUR-Lex at: 
http://eur-lex.europa.eu
Open data from the EU
Th e EU Open Data Portal (http://data.europa.eu/euodp/en) provides 
access to datasets from the EU. Data can be downloaded and reused for 
free, both for commercial and non-commercial purposes.
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About this report
Th e Trends and Developments report presents the 
EMCDDA’s latest analysis of the drug situation in 
Europe. Focusing on illicit drug use, related harms and 
drug supply, the report contains a comprehensive set 
of national data across these themes and key harm 
reduction interventions.
About the EMCDDA
Th e European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confi rmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifi cally sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
Th e EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs fi eld; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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